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The oldest and strongest emotion of 
mankind is fear, and the oldest and 
strongest kind of fear is fear of the 
unknown. 








We can take these Deadites!  
We can take ’em!  
With science! 
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α-Synuclein is an intrinsically disordered protein whose fold and multimeric state is 
strongly affected by its environment. The monomers of α-synuclein are enriched in the 
presynaptic terminals of dopaminergic neurons and seem to have a role in synaptic 
vesicles recycling and transmitter release. Specific cellular conditions can promote 
α-synuclein oligomerization which, in the end, results in neuronal death. Lipids seem 
to be one of these conditions as they are involved in both the native and pathogenic role 
of α-synuclein. This thesis aims to explore α-synuclein:lipid interaction and how 
binding to certain lipids may trigger or suppress oligomerization. Furthermore, it aims 
to establish and use lipidomic techniques for improving the state of knowledge of the 
lipid environment that might affect α-synuclein function and dysfunction.  
In Paper I we investigated how cholesterol, the most abundant lipid in mammals, affect 
α-synuclein affinity towards the lipid bilayer and its oligomerization properties. For this 
work we tested and optimized the preparation of SMA lipid nanodiscs containing 
cholesterol. Then, we used these nanodiscs to investigate lipid-mediated changes in 
fibrillation. We also determined individual amino acid affinities towards the lipid 
bilayer within the α-synuclein primary sequence. The results suggest the existence of 
two binding modes: the N-terminal and NAC binding mode. The N-terminal mode 
seems to be preferred in the presence of anionic lipids (like PG), and this binding leads 
to a delay in fibrillation onset. The NAC-binding mode seems to be promoted in the 
presence of lipid bilayers containing cholesterol and speed up α-synuclein 
oligomerization significantly. 
In Paper II, we focused on lipidomics methods. We established and optimized a method 
for lipid isolation, followed by phospholipid identification and quantification using 31P 
NMR. These methods were first tested on populations of a prokaryotic organism, 
L. innocua, which were arrested at the C/D boundary of its cell cycle. We discovered 
that L. innocua modulates its lipid composition, and both cardiolipin and 
phosphatidylethanolamine fall significantly between the B period and the C/D 
boundary. When we investigated how these lipid changes could affect the physical 
properties models of the cell membrane, we observed that the decrease of PE content 
X 
seems to be compensated for by an increase of PG. In the absence of other factors, this 
would result in decreasing stored curvature stress, while maintaining membrane 
fluidity.  
In Paper III, we used methods established in Paper II for the lipidomic analysis of the 
SH-SY5Y cell line, which is a commonly used neuronal cell model for Parkinson’s 
disease research. We also developed an automated script for analysis of the fatty acid 
chain distribution of phospholipids by LC-MS/MS. We observed several deviations of 
lipid content from commonly used lipid models and lipid content of brain matter. The 
most interesting ones are a high content of PC, low content of SM and PS and absence 




1 Introduction  
Proteins are essential to cellular metabolism and, together with the plasma membrane, 
they form the framework on which cells are built. To fulfil their functions, most proteins 
must fold into a particular three-dimensional architecture, which is determined mainly 
by their amino acid sequence. However, there is the group of proteins which lacks this 
predefined structure coded by amino-acids and is mostly intrinsically disordered. Many 
of these proteins play an essential role in neurodegeneration, like Aβ in Alzheimer’s 
disease, the prion protein (PrP) in Creutzfeldt-Jakob and Kuru-Kuru diseases, or 
α-synuclein in Parkinson’s disease. These diseases are also often referred to as 
misfolding or amyloid forming diseases, to highlight the role of misfolded and 
aggregated protein in their aetiology. Amyloid is a plaque consisting of misfolded 
protein, lipids and other biomolecules appearing in tissue affected by 
neurodegeneration. As the research progress, there is an increasing awareness that the 
cell lipid environments play a crucial role in the progress of these diseases. The lipids 
seem to be important in all stages of a neurodegenerative amyloid disease, from driving 
the misfolding and aggregation of proteins, to explain cytotoxic mechanisms where 
protein oligomers interact with and adversely affect cell membranes, and to 
participation in cell-to-cell amyloid seed transfer.  
1.1 Common features of amyloid fibrils forming proteins  
Between its synthesis on the ribosome and final degradation through proteolysis, there 
is a wide range of states that a protein can adopt through co-and-post translational 
modification, compartmentalization, and interactions with partners. Usually, the 
functional state of protein starts with a monomer fold which is achieved by 
intramolecular interaction within the protein itself (see Figure 1). The resulting tertiary 
units can further assemble into the higher-order functional quaternary structure. In many 
cases, there is a close relationship between the tertiary and quaternary structural level 
and the protein function. In the last two decades, however, it has become increasingly 
recognized that many fully functional proteins do not have well-defined tertiary folds. 
These proteins, often referred to as intrinsically disordered proteins (IDPs), adopts a 
multitude of different conformational states within physiological conditions [1,2]. The 
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amyloid-forming proteins are overrepresented in IDPs group and are very non-typical 
in their folding behaviour. These proteins are notable for their folding instability, or 
more precisely their folding promiscuity, which is driven by their ability to easily form 
intermolecular contact with another monomer of itself or other IDPs. This 
intermolecular interaction could lead to a mainly hydrophobically driven chain-reaction 
leading the formation of nonstructured, amorphous deposits or oligomers which then 
form β-sheet structured aggregates and later amyloid fibrils deposits. These large 
aggregates, both amorphous and structured, are linked with human diseases, and their 
accumulation can (with notable exceptions) be correlated with the pathological progress 
of amyloid diseases.  
 
Figure 1: Energy landscape of possible protein folding pathways. Intramolecular contacts lead 
to a locally stable functional fold which is localized higher on energy plane. Amyloid-forming 
proteins can reach the more energy stable state of amyloid fibrils, usually with the help of 
seeding nuclei. One of the possible agents influencing this behavior of amyloid-forming 





There are currently known 37 peptides which are associated with the formation of 
amyloid deposits (see review [4] for full list). Seven of these proteins are form amyloid 
deposits in the central nervous system in humans and correlate with neurodegenerative 
diseases. An overview of these peptides is in Table 1. These neurodegenerative peptides 
share some similar features like small size and being intrinsically disordered. However, 
there are no other similarities in the sequence, structure or function.  
Table 1: Overview of seven neurodegenerative amyloid-forming proteins and peptides with 






Associated diseases Ref. 
amyloid-β-peptide 40-42 Alzheimer disease 
Hereditary cerebral haemorrhage 
with amyloidosis 
[5,6] 
α-synuclein  140 Parkinson disease 
Dementia with Lewy bodies  
Multiple system atrophy 
[7–9] 




Huntington disease-like 1 
Spongiform encephalopathy  








352-441 Pick disease 







Huntingtin exon 1 103-187 Huntington’s disease [16] 
ABri peptide 34 Familial British dementia [17] 
ADan peptide 34 Familial Danish dementia  [18] 
 
The progress of neurodegenerative amyloid diseases differs, based on which region of 
the brain is affected by cell loss and based on in which region of a brain the amyloid 
plaques will occur later in progress of a disease. However, there are common features 
shared by all neurodegenerative amyloid proteins: (i) the ability to oligomerize from 
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seeds, (ii) form amyloid fibrils with similar structure, (iii) propagate through organism, 
and (iv) to interact with lipids. 
1.1.1 The oligomerization and seeding properties of amyloid-forming proteins  
The amyloid-forming proteins generally have similar aggregation pathways [19–21]. 
These pathways represent a conversion process of normally soluble protein into an 
insoluble, aggregated state, which involves nucleation and growth steps. As presented 
in Figure 1, this aggregation process is part of the protein misfolding process involving 
alterations in protein secondary and tertiary structure [1]. When the quantity of obtained 
fibrils is measured, for example by ThT dye, the sigmoidal kinetics with three distinct 
phases can be observed [22] (Figure 2A). These phases are generally described as a lag 
phase, an exponential (elongation) phase and an equilibrium (saturation) phase. In the 
lag phase, the most population of protein is in monomeric form; however, there is an 
ongoing nucleation process. This oligomerization process is in reversible equilibrium, 
and there is a balance between the assembly and disassembly of oligomers (Figure 2B). 
The next step, nucleation, is fast autocatalytic surface growth, where the equilibrium is 
shifted towards fibrils growth. The assembly process is considerably faster as the 
stability of fibrils is much higher and the concentration of monomers is decreasing 
rapidly. The process ends with saturation, where the monomer population is almost 
depleted, and the assembly and disassembly of fibrils are, again, in a balance. The 
progress of this aggregation can be described by The Finke-Watzky two-step nucleation 
kinetic model [21] (Figure 2C).  
There are some notable known exceptions to this general model. In some cases, it has 
been found that monomers can convert rapidly into unstructured aggregates which are 
not able to support the growth of organized fibrils. Still, it is possible that later these 
aggregates undergo a structural reorganization to generate nucleation seed which 
eventually leads to the formation of fibrils [23]. Moreover, during aggregation, the 
oligomers can follow an alternate pathway which does not lead to final amyloid 





Figure 2: The oligomerization and fibrillation process of amyloid-forming proteins. (A) 
Generic example of the fibrillation process monitored by ThT fluorescence. There are three 
distinct observable phases: (i) a lag phase, where the population of protein is mostly 
monomeric, and where no observable change in fluorescence can be observed. However, in 
this phase, there is already appearance of a minor oligomeric population. (ii)   An elongation 
phase, where the oligomers are rapidly converted into protofilaments which are then elongated 
by monomers. (iii) An equilibrium phase, where the elongation and dissociation of fibrils are 
in equilibrium and the population of monomers is almost completely depleted. (B) Schematic 
overview of the oligomerization processes. This figure panel was replicated with permission 
from [24]. (C) The Finke-Watzky two-step nucleation model, used to describe these processes 
mathematically, is based on two different conversion speeds. The conversion speed from 
monomer (○, white circle) to oligomer (●, black circle) is different from the conversion speed 




1.1.2 The amyloid fibril structure 
There are three features universally accepted as shared properties of amyloid structures: 
a fibrillary morphology, a cross-β structure and an ability to be stained selectively by 
specific dyes. Amyloid fibrils are several micrometers long thread-like structures with 
typical diameters of 7-13 nm and various lengths up to several μm. They are composed 
of 2-8 protofilaments whose turns could either twist around each or be associated 
laterally as flat ribbons [26,27]. The fibrils possess so-called cross-β-architecture which 
refers to laminated β-sheets running along the fibril composed of β-strand which are 
perpendicular to the axis of the fibril [28,29]. These structures can be monitored by 
binding of dyes such as thioflavin-T (ThT), Congo red or their derivatives. The amyloid 
specific dyes bind along surface side-chains grooves running parallel to a fibril’s axis. 
There is interesting morphological and structural similarity of the fibrils formed by 
different polypeptides chains. This can be explained by the dominance of main chain 
interactions, and it seems that amino-acid side chains are playing an only minor role in 
assembly of fibrils [30]. 
The amyloid form is more stable than the native state of the intrinsically disordered 
protein. In organisms, this is a molecular state that leads to irreversible fibril formation 
and later formation of deposits and plaques. Amyloid fibrils have very high 
hydrophobicity — this leads to their interaction with other components of the cell, like 
other hydrophobic protein and lipids and to the formation of insoluble extracellular 
plaques and intracellular bodies [20]. Composition and localization of these plaques and 
bodies vary for different amyloid-forming proteins and different diseases. For example, 
α-synuclein can form intracellular particles in two different cell types with entirely 
different neurodegenerative progress. First types are Lewy bodies, intracellular particles 
in dopaminergic neurons of substantia nigra observed the in Parkinson’s disease (PD) 
patients [31]. Second types are glial cytoplasmic inclusion, formed in oligodendroglia, 
usually not localized to the specific region of the brain [32].   
The remarkable stability of amyloid fibrils become apparent when one considers 
sterilization techniques for working with infectious prions. Typical sterilization 




Creutzfeldt-Jakob patients is the combination of chemical cleaning and pressurised 
steam sterilization at 136°C for at least 18 min [33]. This stability can be explained by 
the arrangement of hydrogen bonds in the amyloid architecture of the β-sheet and by 
the presence of multiple closely interacting sheets. The tight packing of the β-sheets in 
fibrils leads to stable fibrils with lengths in order of microns and tensile strength 
approaching the steal [34]. In nature, the amyloid structures are also used by bacteria to 
form a scaffold for biofilm formation [35]. The amyloid structures have also been used 
in the biotechnology field and led, for example, to the exciting design of nanowires [36], 
metal filters [37] or self-assembly scaffolds for wound healing [38]. 
1.1.3 Prion-like propagation in an organism  
The prion protein (PrP) is, so far, the only neurodegenerative amyloidogenic protein 
that has conclusively been shown to have infectious properties. This infectious 
exogenous prion particles can aggregate with benign PrP molecules present in the 
organism and impose their anomalous structure on them [12,39,40]. The prion particles 
act as a seeding agent that can start the chain reaction of PrP misfolding and 
aggregation. This seeding acceleration is the same which can be observed during 
fibrillation of all the other amyloidogenic proteins, and which can be described by The 
Finke-Watzky two-step nucleation model [21]. This led to the theory that other 
neurodegenerative amyloid proteins are using similar prion-like propagation technique 
via seeds to spread through the organism. The prion-like propagation was indeed 
observed for several amyloidogenic proteins including Aβ, tau, and α-synuclein.  
The experiments showed that Aβ-amyloid rich extract from Alzheimer’s disease 
patients or from mice overexpressing Aβ precursor protein could induce early cerebral 
Aβ-amyloid angiopathy in mice models [41,42]. The induction of Aβ deposits is 
dependent both on the concentration of Aβ seed injected into the organism and on the 
production of human sequence Aβ in a host brain. The injection of control brain 
homogenate, without aggregated Aβ, do not induce amyloid deposit formation in the 
brain of tested mice. Also, selective denaturation of Aβ seeds completely negates the 
ability of brain sample to seed Aβ aggregation [42]. Prion-like propagation of Aβ 
oligomers through brain was also observed, injection of Aβ-rich extract into on 
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neocortex region eventually lead to deposit formation in axonally coupled regions, 
neocortex and allocortex, similar to the progress of Alzheimer’s disease [43,44]. The 
extract was injected directly into the brain through the nose, so these reports serve more 
as a proof of prion-like propagation of Aβ in the organism than proof of possible 
infections properties of Aβ peptide. 
Very similar results have been observed using tau oligomers — the injection of brain 
extract containing aggregated tau into the brain of mouse induced the formation of tau 
lesions which propagates from the injection site to axonally connected areas [45]. 
However, unlike Aβ, the same effect could be observed in non-transgenic mice (not 
overexpressing tau), suggesting that endogenous tau is amyloidogenic at physiological 
concentrations and the simple addition of exogenous seeds is enough to start 
aggregation pathway [46,47].  
Another amyloid protein with experimental evidence indicating its prion-like 
propagation is α-synuclein; this case will be discussed more in depth later. Briefly, the 
first sign of prion behavior in α-synuclein was observed when grafted neuron cells 
containing endogenous α-synuclein seeds led to the development of Lewy bodies from 
11 to 16 years after the surgery in humans [48,49]. The same effect (but in the much 
shorter timeline) has been observed in several in vitro [50–52] and animals studies [53–
55]. Consistent with prion-like behavior, α-synuclein seeds has been showed to generate 
lesions in both transgenic [54,55] (overexpressing α-synuclein) and wild-type mice 
[56,57]. The α-synuclein seeds are also used in the design of new early PD diagnosis. 
In this test cerebrospinal fluid from the patient is mixed with synthetic monomers of 
α-synuclein and early fibrillation, monitored by ThT, indicates positive synucleopathies 
even in the non-symptomatic stage of disease [58].  
1.1.4 Sensitivity to lipid environment 
Another common feature for all neurodegenerative amyloid proteins is their ability to 
interact with the lipid environment. There are two roles of lipid environment in amyloid 
proteins pathogenesis. The first role of the lipids is to regulate the fold and aggregation 
of amyloid-forming proteins. The second role is in amyloid-driven membrane 




membrane properties, including their integrity which can ultimately lead to cell death. 
Following are examples of amyloid-forming proteins interacting with lipids. The 
α-synuclein and lipid interactions are described in detail in different section 
(1.5 α-Synuclein interaction with lipids). 
The oligomeric aggregates of Aβ have been identified to be cytotoxic via membrane 
disruption, which suggests a direct interaction of cytotoxic Aβ species with a lipid 
membrane  [59]. This interaction seems to be highly promoted by anionic lipid 
headgroups, like phosphatidylglycerol (PG) or phosphatidylserine (PS) [60,61]. It has 
also been observed that gangliosides affect Aβ aggregation. Monosialganglioside 
(GM1) has been shown to promote the generation of more toxic Aβ species when 
present in a specific lipid:protein ratios [62,63] and in the presence of lipid-raft 
membrane models [64,65]. It also seems that cholesterol affects the progress of AD, not 
by interacting with Aβ directly but by affecting the processing of Aβ precursor protein, 
which leads to the increased generation of Aβ fragments (reviewed in [66]). The 
mechanism of Aβ toxicity seems to be dysregulation of Ca2+ homeostasis by ion 
channel-like pore formation [67]. However, the annular amyloid pore has been observed 
only in vitro and is disputed by many researchers. Other possible suggested pathological 
processes include membrane thinning or leakage through transmembrane aggregates 
(reviewed in [68]). Nevertheless, the dysregulation of Ca2+ homeostasis has been 
consistent in the pathology of AD, but the mechanism of this regulation disorder and 
the role of lipids in them is still unknown.  
The prion protein is attached to the membrane in mammalian neuronal cells via a 
glycosylphosphatidylinositol anchor [69]. This anchor is necessary for its localization 
in cell and prion-induced neurotoxicity [70,71]. The toxicity of PrP aggregates has been 
correlated with their ability to disrupt and interact with lipid membranes and to affect 
the ionic homeostasis in the cell  [72–75]. The disruption of the membrane by prion 
protein aggregates could be caused by membrane thinning [72,76] or by the formation 
of ion pore channels [73]. The prion proteins (both native and pathological forms) has 
also been found to be associated with lipid rafts containing both cholesterol and 
sphingolipids [77–79], and both of these components seem to be essential for the 
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endocytosis of PrP in epithelial cells [80]. Moreover, it has been observed that early 
association of PrP with lipid rafts stabilizes its conformation in the non-pathological 
state in the early secretory pathways [81].  
There are also reports of in vitro tau oligomers and lipid bilayer interaction. The 
oligomers of tau can disturb a lipid packing and compromise membrane structural 
integrity of anionic lipid vesicles; however, there is no-observed interaction with 
zwitterionic lipids [82,83].  
1.2 α-Synuclein 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease [8]. It was first characterized more than 200 years ago by James 
Parkinson as “Shaking Palsy” [84]. However, it was not until 1997 that connection 
between PD and α-synuclein was established [9,85]. Polymeropoulos et al. [85] 
reported that mutation A53T in SNCA, the α-synuclein gene, was found to be present 
in three Greek families suffering from PD. Simultaneously Spillantini et al. [9] reported 
the presence of α-synuclein in Lewy bodies and Lewy neurites of idiopathic PD and 
dementia with Lewy bodies (DLB) patients. Later it has been discovered that true 
culprits are the oligomers of α-synuclein which are causing the death of dopaminergic 
neurons in substantia nigra [86]. After more than 20 years of intensive research, there 
is an abundance of information about α-synuclein. However, we still don’t have a 
complete picture of the role of α-synuclein in healthy cells, its pathological transition, 
and neurotoxicity mechanism.  
Part of the problem is the complexity of PD. For now, it is impossible to predict if the 
person will acquire PD with 100% accuracy. Still, there are several known elements 
which, to some degree, increase the possibility to acquire PD. These so-called risk 
factors are usually cumulative and if several of them are present the onset of PD can be 
observed in younger age. The risk factors can be gene mutations (such as SNCA or 
GBA), chronical inflammation or a sedentary lifestyle (for the full list see review [87]). 
However, the most of PD cases are still idiopathic (i.e., the cause is unknown) as we 
still don’t see a complete picture of how risk factors in some cases evolve into a full 




which takes place at the molecular level and which involve complex lipid environment. 
Indeed, part of the problem seems to be the effect of lipid environment on the protein 
and difficulty to study this protein/lipid interaction. 
α-Synuclein is a very conservative protein with high sequence similarity in all vertebrae. 
However, some differences between species can be observed. A most notable one is 
that several other mammals, including long-living elephants, have threonine on position 
53 in their wild-type variant of α-synuclein [88]. This substitution is same like 
pathological mutation A53T seen in humans. It is not clear why we cannot see similar 
oligomerization in this non-human α-synuclein molecules. Most probably this is due to 
other single amino-acid differences between molecules, including other substitutions 
(G68E and V95G), which together lowers affinity of α-synuclein to anionic vesicles 
[88]. Nevertheless, the following text is focused only on the human sequence of 
α-synuclein.  
1.2.1 Localization and physiological function of α-synuclein  
α-Synuclein is abundantly expressed in the brain, and it is highly enriched in the nervous 
system [89]. However, some levels of α-synuclein expression have also been detected 
in cerebrospinal fluid (CSF), muscle, kidney, liver, lung, heart, testis, blood vessels, 
blood plasma, platelets, lymphocytes and red blood cell [89–98].  
In the neural cells, α-synuclein is predominantly located in the presynaptic terminal of 
neurons [99,100]. Still, it seems that it does not play an influential role in synapse 
development as it is one of the last presynaptic proteins to become enriched in synaptic 
terminals [101]. Localization to the presynaptic terminal could also be explained by the 
high affinity of α-synuclein towards synaptic vesicle membranes lipids [102,103], or by 
its interaction with the SNARE protein synaptobrevin-2 [104,105]. The physiological 
role of α-synuclein in the presynaptic terminal is not yet fully understood. However, it 
seems that the presence of α-synuclein has a direct effect on synaptic plasticity by 
regulating vesicle packaging and trafficking [106–108].  α-Synuclein seems to regulate 
the number of synaptic vesicles docked at the synapse during neurotransmitter release 
[109], the duration of vesicle fusion with the plasma membrane [110] and the assembly 
of synaptic vesicles [111–113].   
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There are multiple reports that α-synuclein also localizes and binds to mitochondria 
[114–118]. However, this binding is associated more with the pathological effects of 
α-synuclein oligomers, than with physiological role of monomer. Overexpression of 
α-synuclein can lead to fragmentation of mitochondria, disruption of mitochondrial 
membrane integrity and the increased production of reactive oxygen species (ROS) 
[119–121]. Furthermore, in vitro, it was observed that the oligomers of α-synuclein 
could disrupt membranes containing mitochondrial phospholipid cardiolipin [121].  
α-Synuclein localization in the nucleus has been observed since its discovery, hence its 
name [102]. However, since then the reports of its nuclear localization has been 
inconsistent [122–125]. Only phosphorylated α-synuclein at Ser-129 was reported to be 
highly enriched in the nucleus of cultured neurons as well as in cortical neurons of 
transgenic mice that overexpress α-synuclein [126,127]. It has been showed that 
α-synuclein can inhibit histone acetylation [128] and that histone deacetylase inhibitors, 
or knockdown of histone deacetylase – Sirtuin-2, rescue the neurotoxicity of 
α-synuclein both in cell cultures and in Drosophila models [128,129]. Nevertheless, the 
physiological role of phosphorylated α-synuclein in the nucleus is not known. 
There are also reports of α-synuclein association with Golgi complex [130], 
endoplasmic reticulum (ER) [131,132] and with multiple cytoskeletal components in 
vitro [133–135]. However, all of these association are cytotoxic and most probably 
doesn’t play any role in the healthy neuronal cell.   
1.2.3 The structure of α-synuclein  
α-Synuclein is a small, acidic, 140 amino acid long protein with a molecular weight of 
14 kDa (Figure 3). It is composed of three identified domains: the N-terminal lipid-
binding domain (1-60), the amyloid-binding central domain (NAC, 61-95) and the 





Figure 3: Primary structure and fold of α-synuclein. (A) The sequence of α-synuclein divided 
into three distinct sections: N-terminal (red), NAC (green) and C-terminal (blue) with known 
pathological mutations of α-synuclein. (B) Structure of micelle-bound α-synuclein (PDB entry 
1XQ8 [149]). The sections are distinguished by color in the same manner as in panel A. (C) 
Structure of micelle-bound α-synuclein with charged amino acid side chains. The blue and red 
color represents positive and negative charge respectively. Figures in Panel B and C have been 
generated in Pymol software [150]. 
The positively charged N-terminal domain of α-synuclein contains non-perfect 11-
amino acid long repeats. These repeats are highly conserved and unique only to 
vertebrates [136]. Each repeat contains a hexameric motif, KTKEGV, also found in 
apolipoproteins where it represents a small α-helical domain [137]. All pathologic 
mutations associated with PD – A53T, A30P, E46K, G51D, H50Q, and newly identified 
A53E – are clustered within this region [7,85,138–142]. The central NAC region is a 
highly hydrophobic segment that is prone to form inter-molecular cross β-structures 
[143], and it is directly involved in aggregation and fibril formation [144]. The 
C-terminal domain of α-synuclein is an acidic tail. This domain structurally represents 
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a random coil, has low hydrophobicity and high net negative charge. The reduction of 
pH neutralizes the negative charge and induce aggregation in vitro [145,146]. In vivo, 
this domain can be phosphorylated at multiple sites [147,148] which suggest a 
mechanism for regulation. The function of these phosphorylations is still not clear, but 
it has been showed that the C-terminal has a role in both regulating the interaction of 
α-synuclein with lipids [147] and inhibiting oligomerization [148].  
1.2.4 Post-translational modification of α-synuclein 
The α-synuclein can undergo several post-translational modifications in a cell, 
including phosphorylation, nitration, glycosylation, acetylation and truncation with 
various effects on oligomerization and cytotoxic properties of α-synuclein (reviewed in 
[151,152]). However, many of the studies have used an overexpression system without 
a relevant physiological localization of α-synuclein, and most of these modifications are 
likely rare events in normal cell environment [151].  
However, there is one highly relevant post-translational modification of α-synuclein, 
observed in the brains of PD patients, and that is phosphorylation of Ser-129. In the 
brain of the healthy individual only circa 4% of α-synuclein is phosphorylated at this 
position [153]. However, this modification is very prevalent in Lewy bodies in which 
about 90% of α-synuclein is phosphorylated [153,154]. In vivo, it has been observed 
that Ser-129 phosphorylation increased the cytotoxicity of α-synuclein and accelerated 
the formation of α-synuclein inclusions [155,156]. Moreover, the accumulation of 
phosphorylated Ser-129 α-synuclein has been observed in mice models overexpressing 
the α--synuclein [127,157,158]. Furthermore, it has also been shown that 
phosphorylation of Ser-129 can inhibit fibrillation in vitro, potentially producing 
a higher population of toxic oligomers [159,160].  
1.3 α-Synuclein pathology  
α-Synuclein is involved in several neurodegenerative diseases: Parkinson disease (PD), 
Parkinson disease with dementia, Dementia with Lewy bodies, Multiple system atrophy 
and others [4,161]. A common denominator for all of them is the presence of fibril 
deposits containing α-synuclein in the brain. For PD and PD related dementia, the 




eosinophilic, cytoplasmic inclusions, which are particularly numerous in substantia 
nigra [162]. The progress of the PD (and PD related dementia) is associated with 
substantial loss of dopaminergic nerve cells in this region [163]. In Multiple-system 
atrophy the deposits of α-synuclein are found in glial cytoplasmic inclusions which 
resides predominantly in oligodendrocytes [32,164]. The glial deposits are generally 
more spread over the broader region of the brain affecting not only substantia nigra but 
also basal ganglia, cerebellum, spinal cord and other [161,164]. The different 
localization of deposits correlates with the different progress of the disease and different 
clinical symptoms.  
However, the insoluble fibrils deposits of α-synuclein seem to be just a symptom of the 
disease, not its cause. There is accumulating evidence that soluble oligomeric forms 
may be toxic species involved in the disease. Firstly, there is an increase in the 
abundance of oligomeric α-synuclein in the brain of PD patient [165] and this increase 
correlates with the progress of disease [166]. Secondly, in vitro formed oligomers of 
α-synuclein are mostly neurotoxic [86,167,168]. Lastly, more soluble mutants of 
α-synuclein, which are more prone to oligomerization but not to fibrillation, are causing 
dopaminergic death in vivo [86,169]. Meanwhile, the α-synuclein fibrils are mostly inert 
and nontoxic [86]. This evidence points to a molecular basis of neuronal loss which we 
will discuss further.  
1.3.1 Mitochondrial dysfunction  
Mitochondrial dysfunction seems to be central to the pathogenesis of oligomeric 
α-synuclein and has also been described in other neurodegenerative diseases. The 
observations from experimental models and human biopsies provide strong evidence 
that α-synuclein oligomers can induce a mitochondrial depolarization and impair 
respiration through interaction with complex I [116,170], inducing the mitochondrial 
uptake of exogenous calcium [171]. α-Synuclein may also play an indirect role in 
modulating complex I activity by interaction with cardiolipin [172,173]. Cardiolipin, an 
anionic phospholipid, is almost exclusively found in the inner mitochondrial membrane 
[174] and it seems to be involved in the formation of mitochondrial supercomplex. 
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Therefore physical interaction between cardiolipin and α-synuclein could disrupt 
electron transfer [175–177]. 
There are also other theories about α-synuclein-induced mitochondrial death, usually 
backed up by several in vitro experiments. For example, the α-synuclein oligomers have 
been demonstrated to interact with the outer mitochondrial membrane receptor complex 
TOM20 and impair a mitochondrial protein import and an excessive ROS production 
[178]. The oligomers of α-synuclein also seem to be able to induce the selective 
oxidation of the ATP synthase beta unit and mitochondrial lipid peroxidation. These 
oxidation events could lead to a permeability transition pore opening, short-lived 
unspecific pores, which cause mitochondrial swelling and ultimately to cell death [179]. 
Moreover, overexpression of α-synuclein in Caenorhabditis elegans can lead to 
disruption of mitochondrial fusion and mitochondrial fragmentation [120]. These fusion 
deficits can be rescued by overexpressing several PD-related proteins (like PINK1, 
Parkin, and DJ-1) [120,121,180]. Besides, mutant α-synuclein A53T has been shown to 
modulate mitochondria morphology in the central nervous system (CNS) in vivo [181]. 
The reported pathological effect of α-synuclein on the mitochondria is heterogeneous, 
and for now, it is hard to identify which of these pathological pathways (or combination 
of those) are the key one in the progress of synucleinopathy.  
1.3.2 Membrane permeabilization and calcium dysregulation  
The monomers of α-synuclein can bind different synthetic and biological lipids (see 
more in section 1.5. α-Synuclein interaction with lipids). This binding seems to be able 
to initiate the self-aggregation of protein either by raising the local concentration of 
α-synuclein in the presence of membrane, by exposing hydrophobic residues (the NAC 
region) of α-synuclein or by the physiochemical properties of the surrounding lipids 
[182,183]. Once the oligomers are formed, they are able to disrupt the membrane and 
to integrate themselves into the lipid bilayer [184]. This membrane disruption can lead 
to ion flux across the membrane and dysregulation of the most common ion in a cell, 
calcium [168,185,186]. It is not yet known whenever this mechanism is based on a pore 
formation or a membrane disruption (membrane thinning) [187,188]. Recently, there 




interaction of α-synuclein oligomers and cellular PrP and formation of new complex 
hetero-oligomer. This complex can alter calcium homeostasis through interaction with 
metabotropic glutamate receptor and NMDA receptor [189].  
1.3.3 Lysosomal and degradation dysfunction  
Dysfunctional lysosomal clearance mechanism and the failure of the degradation 
pathway to remove the aggregated protein is another phenomenon that accompanies 
oligomer-mediated toxicity. It has been observed that α-synuclein oligomers are cleared 
through the lysosomal pathway and that inhibition of lysosomal activity accelerated the 
oligomer aggregation and toxicity [190]. Conversely, elevated lysosomal activity 
reduces the accumulation of oligomeric α-synuclein in neuronal cell lines [191]. It has 
also been observed that overexpression of transcription factor EB, a master regulator of 
lysosomal biogenesis, was able to reverse the lysosomal defects and accumulation of 
α-synuclein aggregates as more lysosomes were assembled [192]. Another factor is that 
heterozygous mutation in an important lysosomal gene GBA1, coding 
glucocerebrosidase (GCAse), is causing early onset and faster progress of PD in 7% of 
cases [193]. It is not yet clear how 30-50% reduction of GCAse concentration in a cell 
can cause an increase in oligomerization of α-synuclein. The theory is that this is caused 
by the accumulation of GCAse substrate, glucosylceramide (GluCer), which can 
directly interact with α-synuclein and promote the conformational conversion of 
α-synuclein monomers, into toxic oligomeric species [194].  
1.3.4 Oxidative stress 
Oxidative stress is another important pathological hallmark of α-synuclein oligomers 
presence [195]. It is caused by an imbalance between ROS species like O2-, H2O2 and 
O., and antioxidants such as glutathione or enzymes such as manganese superoxidase 
dismutase [196,197]. The increased oxidative stress comes partially from disturbing the 
mitochondria homeostasis. The mitochondria are the major intracellular source of ROS, 
generated in Complex I and II of the respiratory chain. Any disturbance in mitochondria 
integrity can lead to the release of ROS to intracellular space of the cell [198]. However, 
oligomeric α-synuclein seems also to produce ROS independently of known 
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mitochondrial enzymatic pathways [199,200], and it is also able to induce increased 
lipid peroxidation activity [200].   
1.3.5 Microglial activation and inflammation 
Microglial activation is the critical component in the progress of amyloid 
neurodegenerative pathogenesis. The release of protein aggregates and oligomers from 
neurons activates microglia which consequently initiates an inflammation response 
[201]. The activation of microglia then results in elevation of cytokines, chemokines, 
ROS and interleukin levels which are crucially involved in neuronal death [202]. There 
are two mechanisms of α-synuclein associated microglia activation. The first one 
happens when α-synuclein oligomers are taken up by an astroglial cell where they 
trigger an inflammatory response [190]. The second mechanism is the interaction of 
α-synuclein oligomers and Toll-like receptors on both microglia and astrocytes [203–
205].  
The microglial activation can be viewed as a double-edged sword in neurodegenerative 
diseases. On the one hand, microglial activation is necessary to clear debris from 
apoptotic neurons, but on the other, it contributes to cell stress by an increasing the 
amount of ROS, cytokines, and chemokines [206]. The inflammation processes in a 
brain can also be viewed as a positive feedback loop: α-synuclein oligomers and 
aggregates can induce inflammation processes which then promotes even more 
oligomerization and aggregation.  It has also been observed that other processes which 
lead to microglial activation can lead to faster progress of some neurodegenerative 
diseases. For example, traumatic brain injury can lead to an increase of the 
concentration of pro-inflammatory and amyloidogenic protein S100A9 and 
consequently into Aβ aggregation and AD [207]. It is possible that similar inflammatory 
positive feedback loop is present also for α-synuclein. 
1.4 Folding, oligomerization and fibrillation of α-synuclein  
α-Synuclein is structurally exciting protein. In its native state the protein is intrinsically 
disordered, but under specific conditions, it can gain α-helix structure, β-sheet structure 
or cross β-sheet fibrillary structure. This quite unusual behavior has led to the 




1.4.1 Native monomeric α-synuclein 
In the cell, α-synuclein exists in equilibrium between a soluble and a membrane-bound 
state [151]. The soluble α-synuclein is primarily monomeric and intrinsically disordered 
[209,210]. The intrinsically disordered proteins have little or no ordered structure under 
physiological conditions and fall mostly into the category of random coils [208]. 
However, it was observed that α-synuclein monomers are slightly more compact than 
expected [211,212]. Further FTIR and NMR analysis revealed that ~ 70% of molecules 
is disordered, but a region between residue K6 and V37 has a preference towards helical 
conformation [211,213]. The possibility of a helical conformational presence in 
monomeric α-synuclein has also been confirmed by Raman spectroscopy [214]. The 
partial folding is visible at higher temperatures or low pH [211,212]. Lower pH can 
neutralize the excess negative charge of α-synuclein (pI = 4.7), increase the overall 
hydrophobicity of the protein and induce the helical formation on N-terminal. This pH-
induced transition from unfolded to partially folded conformation was shown to be a 
completely reversible [211,212]. 
Upon binding to a membrane α-synuclein monomer will adopt α-helical structure on 
the N-terminal part of the protein [215–217]. Overall, the N-terminal ~100 amino acids 
will gain an α-helical conformation while the remaining ~40 amino acid in the C-
terminal region stay unordered [218,219]. The truncation of the N-terminal domain has 
been showed to reduce lipid binding drastically and suggest a cooperative effect of the 
11-residue repeats present in this region [151]. However, there are different reported 
structures where α-synuclein forms either a single extended helix or a helix broken 
around a central bend. It was later elucidated that these structural variations depend on 
the membrane curvature. Specifically, membranes with a larger diameter (>30 nm), 
which have lower curvature, induce an elongated α-helix in α-synuclein [218–221]. 
Meanwhile, when α-synuclein interacts with small highly curved vesicles, it adopts a 




Figure 4: Membrane-bound α-synuclein. (A) When bound to a vesicle, α-synuclein has been 
reported to obtain an extended helical conformation [218]. (B, C) When bound to lipid models 
of smaller diameter, α-synuclein adopts the structure of a broken helix (PDB entry 1XQ8 and 
2KKW, for panel B and C respectively) [149,225]. SDS - sodium dodecyl sulphate, SLAS - 
sodium lauroyl sarcosinate. The figure was replicated with permission from [226].  
1.4.2 Dimers, Trimers, and Tetramers 
There are two different structural variants of α-synuclein dimers referred to as the type 
1 and type 2, both of them quite unstable and transient [227]. The type 1 dimer is more 
unstable with a lifetime around ~100 ms in neutral pH [228], and both molecules of 
α-synuclein in the dimer have similar globular shape [229]. The type 1 dimers form 
preferentially in certain circumstances, for example, by the mutant A30P, which is 
predisposed to form oligomers over fibrils in vitro. Both molecules in type 1 dimer seem 
to have only a single point of intermolecular contact [230,231], which explain type 1 
dimer short lifetime. The type 2 dimer is less abundant (~ 20 % of dimers for wild-type 
α-synuclein) in neutral pH, but it is more stable with longer lifetime ~500ms [228]. The 
type 2 dimer population becomes more abundant in lower pH, probably due to 
stabilization of negative charge on C-terminal of protein. It was also shown that dimers 
from α-synuclein mutants E46K and A53T, which are more prone to fibrillation, have 
multiple intermolecular contacts and are more stable [230,231]. Structurally, the type 2 
dimer consists of one globular molecule and one molecule with extended flexible tail 
[229]. The extended part of α-synuclein seems to be the N-terminal, forming a 
metastable α-helix [229]. This observation has led to the theory that lipid bilayer could 
lead to stabilization of type 2 dimer and through this mechanism to the promotion of 




Trimers of α-synuclein are rarely studied as they seem to exist only in a mixed 
population with oligomers. There is one study which points out trimers in the mixture 
of small oligomers as a possible cause of in vitro liposome clustering (the model of 
mitochondrial fragmentation) [121]. α-synuclein trimers have also been identified in the 
presence of phosphoglycerol (PG) and oleic acid. In the presence of lipid molecules, 
α-synuclein has been observed to form trimeric nanoparticles, similar to the ones 
formed by apolipoprotein, i.e., ellipsoidal discs with a diameter of ~10 nm. In this 
trimeric form, α-synuclein seem to assume a broken helical conformation [232].  
Native α-synuclein tetramers have been reported in 2012 [233]. The α-helical tetramer 
is hypothesized to be a non-toxic species that inhibits α-synuclein fibrillation pathway 
[234] and that up to 70% of native cytosolic α-synuclein is in this form [235]. Several 
studies have confirmed the observation of tetramers in the native neuronal cell 
[235,236], however other groups were unable to confirm this [209,237]. So, for now, 
the existence of tetramers in vivo remains a polarizing issue in the field [209].    
1.4.3 On and Off-pathway α-synuclein oligomers  
There is still little consensus on the exact mechanism of α-synuclein toxicity. However, 
soluble oligomers are widely regarded as the main culprit of PD and other 
synucleopathies. When analyzed by atomic force microscopy (AFM), the different 
morphologies of early oligomers were observed [208]. The early oligomers appeared to 
be predominantly spherical with a radius between 2.5 and 4.2 nm [238,239]. They are 
later converted into annular (doughnut) shape under appropriate conditions. The wild-
type of α-synuclein seems to produce two types of annular structures: small, with a 
diameter range of 32-96 nm, and large, with a diameter range of 100 – 180 nm [239]. 
The PD-associated pathological mutations A53T was observed to form a smaller and 
more homogenous population of annular oligomers with diameter ~10 nm. It was 
suggested that the observed annular oligomers are not on the direct monomer-to-fibril 
pathway and that these annular structures must be reopened to be converted to fibrils 
[239]. The round shape oligomers can interact with phospholipid bilayers and are able 
to induce membrane permeabilization [240]. Another observed morphology of 
α-synuclein oligomers is rod shape. The rod-shape oligomers are formed when 
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α-synuclein binds dopamine which seems to be incorporated into the structure of the 
oligomer. These rod oligomers do not bind phospholipids or affect membrane 
permeability [241]. Stellate oligomers (star-shaped) have been observed in vitro in the 
presence of copper, these oligomers have also reduced the ability to associate with 
membranes [242,243]. It is not yet certain which of these species exist in vivo.  
The early oligomers are transient, and they seem to be able disassemble into monomeric 
form. Still, there are several studies which have been able to use the modification of 
α-synuclein to isolate a stable homogenous population of oligomeric species. These 
modifications are: the oxidation of the methionine residues to methionine sulfoxide 
[244,245], the nitration of tyrosine residues [246,247], the interaction with polyphenols 
such as baicalein, rifampicin, epigallocatechin gallate (EGCG) [248–250], the covalent 
modification by 4-hydroxynonenal [251] or the tandem repeats of α-synuclein 
connected by peptide linker [252]. Many of these oligomers are incredibly stable with 
a prolonged rate of both dissociation and fibrillation. However, they are generally much 
less toxic than in vivo isolated oligomers suggesting they are biologically less relevant, 
inert, off-pathway oligomers.  
Recently more insight into the structural difference between toxic and non-toxic 
oligomers of α-synuclein has been published [184]. Two general types of oligomers 
have been established – type A* and type B*. Both types have similar sizes and 
morphologies. However, they exhibit different abilities to disrupt the lipid bilayer. Type 
A* is the non-toxic type which can be generated, for example, by incubation of 
α-synuclein monomers with EGCG [248]. These oligomers can interact with 
membranes but do not to disrupt them [184]. Type A* oligomers are predominantly 
unstructured and have limited interaction with charged lipid headgroups, but no deep 
penetration into the membrane. Type B* oligomers are neurotoxic oligomers, generated 
by prolonged incubation of α-synuclein in 37 °C with shaking. They are able to interact 
with the membrane, and they induce membrane leakage in vesicle models [184]. 
Structurally, type B* oligomers contain both α-helix and β-sheet structures. It is 
hypothesized that α-helix interacts with charged lipid headgroups and β-sheets 





Figure 5: Two different types of α-synuclein oligomers. Type-A* oligomers, generated by 
incubation with EGCG, do not penetrate the lipid bilayer and are mostly unstructured. Type-
B* oligomers, generated by incubation at 37 °C and shaking, penetrates lipid bilayer and 
contains both distinct α-helix and β-sheet domains. The figure was replicated with permission 
from [184].   
1.4.4 Fibrils of α-synuclein  
There are two final stages of α-synuclein aggregation pathway: amorphous aggregates 
and structured fibrils. The amorphous aggregate has only been observed in vitro, and it 
is similar to precipitation of non-amyloid proteins. It represents a non-reversible 
collapse into particles with highly hydrophobic cores [208,253]. The fibrillation is 
a more delicate process which contains a high amount of oligomer restructuralization.  
During fibrillation, the α-synuclein oligomers assemble into a highly compact structure 
enriched in β-sheet content [254–256]. The core is formed mainly by NAC and by part 
of N-terminal domain, from residues 30-38 to residues 95-110, which are assembled 
into five to six β-strands separated by several loops [257,258]. The N- and C-terminal 
regions are unstructured and exposed to the solvent outside of the core. There are 
various fibril structures reported by AFM and by transmission electron microscopy and 
fulfill all general characteristics of amyloid fibril (1.1.1 Amyloid fibril structure). 
However, different subtypes of the α-synuclein fibrils has been characterized: twisted, 
curved, periodic, untwisted, straight and nonperiodic [259,260]. Such variability is 
caused by different aggregating conditions, or it can be the effect of the genetic 
mutation. Overall it is virtually impossible to define which of the observed structure 




Fibrils do not appear to be toxic on its own. However, there are two fibril toxicity 
hypotheses, which are backed by several reports [227,253]. The first hypothesis is that 
fibrils can produce toxic oligomers by a dynamic equilibrium with fibril 
assembly/disassembly. It has been observed that when monomers are removed, the 
fibrils can slowly dissemble and generate a mixture of oligomers and monomers [167]. 
The products of fibril disassembly can serve as a seed to the growth of new fibrils from 
free monomers. This phenomenon also appears in vivo during apparent cell-to-cell 
transmission [50,53]. In addition, pre-formed fibrils applied to neuronal cell culture are 
able to seed the growth of endogenous α-synuclein aggregates, even in the absence of 
endogenous overexpression [261]. Moreover, there have been reports where cells 
seeded with α-synuclein aggregates shown the disruption of autophagic protein 
clearance and calcium homeostasis dysfunction [262].  
The second fibril toxicity theory is that the process of fibril elongation is toxic through 
the phenomenon of “lipid extraction,” which was initially observed in studies of 
amyloidogenic human islet amyloid polypeptide [263]. It has been observed that 
α-synuclein fibrils can absorb fluorescently labeled lipids. This effect accelerated when 
A53T and E57K α-synuclein mutants were used. However, the addition of dopamine 
prevents this binding, probably by stabilizing soluble oligomers [264]. So far, the lipid 
extraction has not been studied in cells, but it has been shown that fibrils can disrupt 
lysosomes and mitochondria isolated from cells [265]. The fibrils have also been shown 
to disrupt vesicles with smaller amounts of anionic lipids (from 20% of PG) than what 
was observed in the case of oligomers (from 50% of PG) [266,267]. This observation 
suggests the possibility that there is a different permeabilization mechanism for fibrils 
than the one described for oligomers.  
1.5 α-Synuclein interaction with lipids  
The lipid environment is an essential component in both the biological and pathological 
role of α-synuclein. The interaction between α-synuclein and the membrane has been 
found to affect not only properties of the protein but also those of the lipid membrane. 
It has been observed that α-synuclein presence in the membrane has an effect on its 




membrane thinning and membrane expansion [271,273]. Summary of α-synuclein and 
lipid interaction is in Figure 6.  
The strength of α-synuclein binding to the lipid bilayer is affected by the membrane 
physical, chemical, and thermotropic properties. α-Synuclein binds preferably to: (i) 
membranes composed of negatively charged (anionic) phospholipids [112,274], (ii) 
membranes containing packing defects [273,275] and/or (iii) membranes in fluid phase 
[183,269]. From these three components, the effect of electrostatic interaction (negative 
charge on the membrane) is the strongest contributor to final binding affinity. This has 
been confirmed by the observation that change in ionic strength of buffer has a 
noticeable effect on α-synuclein lipid binding efficiency [60,215]. 
Although, structural information about α-synuclein bounded to lipid membrane has 
been characterized previously [111,276], the detail of binding and the mechanism by 
which lipid environment affects folding and aggregation of α-synuclein is not yet well 
understood. Part of the problem was that it was not until recently, that intro experiments 
elucidated that this effect is strongly dependent on lipid:protein ratio (L:P ratio) 
[182,277].  
One molecule of α-synuclein can interact with n molecules of lipids. The n values differ 
between different lipid species and their mixtures [277]. For L:P molar ratios < n there 
is an insufficient amount of binding places on lipid bilayer, and α-synuclein monomers 
compete for binding. This could lead to local upconcentration of α-synuclein which will 
affect both the oligomerization and toxic properties of oligomers, in particular those 
related to membrane damage. Bound α-synuclein on the lipid membrane can also serve 
as a nucleation site, and in combination with an excess of free monomers, this promotes 
faster oligomerization and aggregation.  When L:P ratio is closer to the n value, the rate 
of oligomerization slows down as there are less available monomers in solution. 




1.5.1 Anionic phospholipids 
It has been observed that α-synuclein favorably interacts with lipid system containing 
anionic phospholipids like PG or PS [182,183,278]. During this interaction, there is a 
change in the fold of α-synuclein monomers from the intrinsic disordered state into the 
α-helical fold (see section 1.4.1. Native monomeric α-synuclein). The newly formed α-
helix binds the bilayer by interaction with lipid headgroups, and this binding affects the 
aggregation properties of α-synuclein. However, the results of how precisely the 
presence of anionic lipids affect oligomerization and aggregation properties were 
inconclusive. Some studies observed promotion of aggregation and an increase in 
toxicity [278,279], and others reported a decrease in aggregation [182,183]. It is 
believed that these conflicting reports arise from different L:P ratio used in different 
experiments (for more information see review [277]).    
 
Figure 6: α-Synuclein interaction with lipids. α-Synuclein is able to interact with anionic lipids 
(in the picture: DOPS and DOPG) and sphingomyelin (in the picture:  SM d18:1/16:0). Upon 
binding to the lipid bilayer, monomers of α-synuclein converts to a mainly α-helical 
conformation. α-Synuclein is also able to interact with cholesterol. The cholesterol binding 
sites are highlighted in green. Generally, α-synuclein does not interact with zwitterionic lipid 
bilayers (in the picture: DOPC), other factors (like high stored curvature stress in lipid vesicles) 




It has also been observed that α-synuclein is co-localizing with synaptic vesicles in live 
cells which contains large amounts of anionic phospholipids [102] and the presence of 
anionic lipids and high curvature seems to be driving force behind α-synuclein 
localization into presynaptic vesicles of neuronal cells [273,277].  
1.5.2 Sphingolipids 
Sphingolipids have been the main suspect in more pronounced α-synuclein aggregation. 
The reason is that mutation of the GBA1 (gene coding GCase) is the most critical risk 
factor associated with PD. GCase converts GluCer to glucose and ceramide and the 
decrease in its activity leads to the accumulation of its substrates GluCer and 
glycosylsphingosine [194,280,281]. Mutation of GCase is associated with lysosomal 
degradation, which is one of the syndromes associated with synucleopathies (see 1.3.3 
Lysosomal degradation and dysfunction for more information). However, elevated 
levels of several sphingolipids, including lactosylceramide, GM2, GD3 or GM3 has 
also been observed in Parkinson mice models [194] or the blood plasma of PD patients 
[282].  
Two independent reports have found that Lewy bodies contain sphingolipids in its 
central core, especially sphingomyelin [283,284]. This was later confirmed using 
cellular models [285]. The sphingolipids, in general, seem to affect the ability of 
monomeric α-synuclein to bind to the membrane [286]. This interaction between α-
synuclein and sphingolipids is in many ways similar to the interaction between α-
synuclein and the anionic lipids. Both sphingolipids and anionic lipids seem to promote 
α-synuclein association with the membrane. Out of all sphingolipids species, α-
synuclein has the highest affinity towards ganglioside GM1. The mixture of GM1 and 
DPPC (ratio 1:1) binds five times more molecules of α-synuclein than DPPC only [277].   
In aggregation experiments, it was observed the vesicles containing sphingolipids are 
inhibiting oligomerization and aggregation of α-synuclein [278,286] Indeed, in this 
conditions a fraction of α-synuclein monomers is bound to the membrane which leads 
to the absence of available monomers which continue on the oligomerization pathway. 
However unlike for other tested anionic vesicles like DPPC or DMPS, in sphingolipid 
aggregating experiment, only lag phase seem to be affected and not fibrillation rate. 
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This suggest that, unlike anionic phospholipids, sphingolipids mainly affects the 
primary nucleation speed of α-synuclein, but once seeds are formed, the inhibition of 
oligomerization by sphingomyelins cease to have an effect [277,287].  
1.5.3 Cholesterol  
Cholesterol is one of the most abundant lipid species in the brain, and its dysregulation 
has been linked to faster progression of several neurodegenerative diseases including 
Alzheimer’s disease [288,289], Huntington’s disease [290] and Niemann-Pick disease 
type C [291,292]. However, the relationship between cholesterol and PD is less clear. 
Cholesterol is synthesized in brain de novo and cannot cross blood-brain barrier [293], 
and blood plasma levels of cholesterol do not reflect the abundance of cholesterol in the 
brain. This has led to contraindicating observations that elevated serum levels of 
cholesterol are related to an increased risk of PD [294], a decrease of risk of PD [295] 
or not correlated with PD at all [296,297]. However, the metabolites of cholesterol, like 
27-hydroxycholesterol (27-OHC) are able to cross the blood-brain barrier freely and 
bear more accurate representation of total cholesterol abundance [293,298]. Indeed, it 
was observed that 27-OHC is more abundant in PD patients [299].   
Nonetheless, a direct molecular link between the presence of cholesterol and 
α-synuclein fibrillation is still missing. This is because high cholesterol concentration 
in the cell could lead to α-synuclein fibrillation via other cellular processes other than 
direct α-synuclein/cholesterol interaction [277]. For example, a high concentration of 
cholesterol is known to affect lysosomal activity by inhibiting maturation of late 
endosomes into lysosomes [300–302]. This leads to a disruption of lysosomal activity, 
similar to that observed in the case of GCase deficiency. Insufficient clearing of 
α-synuclein monomers can favour oligomerization rate and can lead to toxic effects 
[280]. Moreover, the observed increased levels of 27-OHC could be the result of PD, 
not its cause. The increased oxidation of cholesterol sign of ROS presence generated by 
mitochondrial damage during the progress of PD [303]. However, in vitro experiment 
showed that α-synuclein molecule could interact with cholesterol directly. 
The NAC region of α-synuclein has been reported to contain two cholesterol binding 




[304,305]. The second binding site was used to design cholesterol-binding peptide, 
further proving high cholesterol binding ability. It was also reported that α-synuclein 
could serve as cholesterol acceptor and with combination with transmembrane protein 
ABCA1 it can promote cholesterol efflux from membrane [306]. Also, the formation of 
“amyloid pores” by α-synuclein oligomers has been reported to be possible only in the 
presence of cholesterol-rich membranes [304]. If such findings are verified, it would 
suggest that cholesterol could play an essential role in the toxic effect of α-synuclein 
oligomers. The other reports are inconclusive as cholesterol seems to promote [106], 
inhibit [307,308] or not affect [183] α-synuclein interaction with lipids. The role of 
cholesterol in α-synuclein physiological and pathological activity is yet to be entirely 
determined as the molecular mechanism behind this interaction is still poorly 
understood.  
1.6 Neurolipidomics 
The interaction between lipids and other amyloid proteins, including α-synuclein, is an 
active research field with many questions left unanswered. Among the most critical 
questions are: Which lipids come into direct contact with amyloid proteins? In what 
amounts do they occur in different tissues and subcellular compartments? How do they 
affect risks for developing misfolding diseases and how do lipid profiles change as the 
disease progresses? These questions are part of the driving forces behind amyloid 
neurolipidomics research [309].  
It has been reported that the human brain is composed of around 900 neuroanatomically 
different subdivisions and each of these subdivisions have a different region-specific 
protein transcription profile [310]. This could lead to the assumption that also lipid 
composition is region specific or at least have some regional variation. However, this 
area of research is limited, and for now, we lack region and cell-specific lipidomics 
information. The focus of this section is to present current neurolipidomics knowledge 
with a focus on lipids which can be observed by 31P NMR, i.e. the lipids containing 
phosphor atom. These are phospholipid species, cardiolipins, and sphingomyelins.  
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1.6.1 Lipid composition of brain   
The adult human brain contains almost most of the human lipid mass, second only to 
the adipose tissue [311]. Lipids constitute around 5% of the wet weight of the whole 
brain and 7% of white matter. The brain lipids are also the most diverse, compared to 
other organs, and they consist of possible thousands of phospholipid and sphingolipid 
molecular species [312]. Brain tissue also contains an abundance of cholesterol. Indeed, 
one-quarter of total body cholesterol is localized in the brain, making it the organ with 
the highest concentration of cholesterol in the human body [313]. For a summary of 
brain lipid composition see Figure 7.  
Quantitatively, the most abundant phospholipids isolated from brain matter are 
phosphatidylethanolamine (PE) [312,314–316]. They constitute about 35-36 % of all 
phospholipids in the human brain. The most of brain PE is in the form of ethanolamine 
plasmalogen or diacyl. The alkylacyl analogs of PE constitute less than 7% of total PE 
content in the brain. Regarding fatty acid (FA) composition, it has been reported that 
sn-1 position is usually occupied by palmitic (16:0), stearic (18:0) or oleic acid (18:1). 
Position-2 contains more polyunsaturated FA chains. The second most abundant brain 
phospholipid is phosphatidylcholine (PC; ~30% of brain phospholipids) [314,315,317–
319]. It is also the most predominant form of choline in the human brain. The major 
species is PC (16:0/18:1), and other forms of PC are reported to be in the minority. The 
choline plasmalogen and alkyl analogs account only for about 2% of total PC in the 
brain. The last major phospholipid group is formed by phosphatidylserines (PS) making 
up to ~17% of total phospholipids [314–316]. More than 90% of PS are in the form of 
diacyl, with the rest being mainly in plasmalogen form. FA profile of PS is composed 
mostly of steric (18:0), oleic (18:1) and docosahexaenoic acid (22:6). The long, 
unsaturated 22:6 chains of PS were observed particularly in the grey matter.  
The phosphatidic acid (PA) is a minor phospholipid brain component (~3%) [312,314]. 
It is the simplest glycerophospholipid, and it is a central intermediary in the synthesis 
of both glycerophospholipids and neutral lipids. Another minor phospholipid 
component is phosphatidylinositol (PI) (~2%) [319,320]. The relative abundance of PI 




highest concentration of PI found among animal tissue.  The main FA components of 
PI are steric (18:0) and arachidonic acid (20:4). Lastly, minor phospholipid components 
of the brain (less than 1%) are glycerol phosphatidylglycerol (PG) which include mainly 
its diacyl form and bis(monoacylglycerol) phosphate [321]. PG has been reported to 
have a wide range of FAs including 16:0, 16:1, 18:0, 18:1, 18:2, 18:3 and 20:4 and to 
be localized in the mitochondria, nuclear and synaptosomal fraction. 
Phosphatidylglycerol is also a metabolite precursor of cardiolipin, which is a specific 
type of diphosphatidylglycerol localized exclusively into inner leaflet of mitochondria 
[322].  
 
Figure 7: Phospholipid (including sphingomyelin) composition of the brain. Data taken from 
[312].  
Sphingolipids are the second biggest group of complex brains observed in brain tissue. 
They are derived from N-acylsphingosine (ceramide) which is also the most abundant 
sphingolipid species [323,324]. A different modification of sphingolipid headgroup 
leads to the formation of sphingomyelin, cerebrosides, sulfatides, and gangliosides. 
Sphingomyelin (N-acylsphingosine-1-phosphocholine) is primary lipid of myelin 
membrane, and it is found in high concentration in peripheral nerves and white matter, 
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and it consists of ~12% of phospholipids in the brain [314,315,317,318]. Sphingomyelin 
FA chains comprise mainly of stearic (18:0), lignoceric (24:0) and nervonic acid (24:1).  
1.6.2 Brain phospholipid changes during aging and Parkinson disease 
The human brain ability to perform its wide range of functions decline with age, like 
any other part of the human body and this decline is even more pronounced during the 
progress of neurodegenerative diseases. It was observed that deterioration in structure 
and function is not uniform throughout the brain. It seems that brain aging and 
neurodegenerative processes are region- and cell-specific [312]. This phenomenon is 
called selective neuronal vulnerability (SNV), and it has been observed during the 
neurodegeneration, including both Alzheimer (AD) and Parkinson’s disease (PD) [325–
328]. The mechanism of SNV is still unknown, and this hinders further understanding 
of the neurodegeneration. One of the possible causes of SNV could be different regional 
lipid composition. 
Regional SNV has been confirmed for both aging and neurodegenerative changes. 
During aging, the most affected brain regions are the association cortex, the neostriatum 
and the cerebellum [329–331]. For AD, the most affected region is the CA1 region of 
the hippocampus [332], and for PD it is substantia nigra [328]. The difference between 
these regions is studied by various techniques, including histological analysis, 
neuroimaging, and genomic and proteomic profiling. In these studies, however, the 
possible role of membrane lipids and lipid metabolism is mostly ignored. This is true 
even despite the knowledge that neuronal loss in these sensitive regions is relatively 
modest and most of the neurodegenerative processes are caused by changes in a number 
of synapses. The synapse can be affected by relatively subtle changes, like loss of 
dendrites, reduction in spine densities, altered spine morphologies or changes in the 
molecular profile of synapse [312,326,330]. All these changes can be associated with 
alteration of cell lipid profile. 
Whole brain lipid analysis showed that the total amount of lipids increases until the age 
of 20 and then starts to decline [312,319,333]. This decrease speeds up after the age of 
50. However, it is still very slow for several monitored phospholipids lipids: PI, PE, and 




species where the observed decline was more pronounced; ethanolamine plasmalogen 
(PPE) and sphingomyelin [334]. The decrease is almost twice as fast as when compared 
to other lipid species and in case of PPE human brain lose 29% of PPE and 20% of 
sphingomyelin at age 100.  
The study of regional brain lipid composition is limited, and so far such analyses have 
only been performed concerning FAs and cholesterol. McNamara et al. [335] observed 
that age inversely correlates with the amount of polyunsaturated fatty acids (PUFA), 
mainly docosahexaenoic (22:6) and lignoceric acid (20:4) in the grey matter of the 
orbitofrontal complex (decrease of 15% between groups of 30 and 80 years old). This 
age-related reduction in PUFA composition is inversely correlated with increased 
stearoyl-CoA desaturase activity, resulting in elevated levels of monounsaturated FAs. 
Regional cholesterol content seems to follow a similar trend as PUFA and its amount 
in brain decrease with age. So far, the decrease of cholesterol was observed in human 
frontal and temporal cortices, hippocampus, nucleus caudatus, medulla oblongata, and 
cerebellum. However, the rate of reduction in cholesterol content seems to be region-
dependent, possibly mirroring differences in metabolic need if each specific region. 
[334,336].  
There is a limited number of studies focusing on the lipidomics changes of the brain 
during the progress of PD. In the substantia nigra, it has been observed that there is the 
elevated activity of phospholipid biosynthetic enzymes relative [337] and there is an 
increase in cholesterol levels [338] relative to the rest of the brain. However, this 
increase has not been quantified. In the frontal cortex, there was a significant increase 
in diacylglycerol levels, similar to the increase observed in the frontal cortex of AD 
patients [339]. When the primary visual cortex of PD patients was investigated, changes 
in the lipid metabolism pathways of phosphoglycerol and cholesterol were observed 
[299]. Increase in levels of 24-OH cholesterol was observed. In response to that, the 
whole antioxidant response genes apparatus was upregulated. In the 
glycerophospholipid pathway, upregulation of the gene producing CDP-choline, the 
primary substrate for PC production, was found. However, the levels of PC remained 
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unchanged. Instead, there was an increase in the levels of PS, which suggest that excess 
of PC was metabolized into PS lipid species.  
During aging, the overall levels of lipid in the brain dropping. However, during the 
progress of amyloid-forming neurodegenerative diseases, like PD, there is an apparent 
trend of upregulation of specific lipids in different areas of the brain. From current 
knowledge, most interesting is observed increased concentration of cholesterol and 
24-OH cholesterol in the substantia nigra, most vulnerable part of the brain in PD.  
1.7 Lipid nanodiscs - a tool for studying lipid-protein interactions  
Research of how amyloid proteins interact with lipids is hindered by the complexity of 
natural lipid bilayers and by inadequate lipid models. The lipid vesicles are currently 
most commonly used lipid models. However, they suffer from several drawbacks like 
little stability or high-scattering.  They also bring severe limitations to solution NMR 
experiments due to their size and high tumbling times. When searching for more 
suitable lipid model, it is possible to take into account α-synuclein behavior as a 
peripheral protein. This line of thought leads to novel lipid models used in membrane 
protein research, lipid nanodiscs (reviewed [340,341]).  
Lipid nanodiscs are planar patches of the bilayer with diameters in the range of tens of 
nanometres. The lipids are encircled by amphipathic scaffold species which envelops 
lipids as a belt. Nanodiscs, along with micelles, bicelles, liposomes, and other colloid 
systems, belongs to the class of self-assembly lipid particles with defined structures 
[342]. These structures are in dynamic equilibrium with its environment, potentially 
exchanging their components. [340]. Compared to other self-assembled systems, the 
lipid nanodiscs are more stable and structurally better defined. The nanodiscs are not an 
entirely thermodynamically stable state of mixture of lipids and scaffold polymers as it 
has been observed that after prolonged incubation at increased temperature, they tend 
to separate irreversibly [343,344]. However, at physiological temperatures the stability 
is sufficient, and lipid nanodiscs can be stored for months at 4 °C with minimal 
aggregation and size variation. The scaffold species used in for lipid nanodiscs 
preparation can be either a membrane scaffold protein (MSP) or a non-peptide polymer 




Originally, MSP was based on apolipoprotein A1 sequence [345]. This protein, 
however, produced a variety of lipoprotein particles of different sizes. Authors then 
modified the original protein several times to obtain more homogeneous and stable 
nanodiscs. The first modifications were extensions with additional α-helices, which 
yielded a larger protein envelope and resulted in larger and better-defined populations 
of lipid nanodiscs [346,347]. Later it was discovered that the N-terminal of the protein 
did not participate in the formation of the peripheral protein belt and after its deletion, 
the size of the formed nanodiscs were more homogeneous [346]. This version is denoted 
MSP1D1 and is currently the most commonly used in protein-lipid nanodisc 
preparation. One drawback of protein nanodiscs is the necessity to use detergent in their 
preparation. The lipid mixture needs to be dissolved in a detergent environment, and 
after addition of MSP protein, the detergent is removed by detergent absorbing particles. 
The lipid nanodiscs are then formed by self-assembly [343,344]. The preparation of 
lipid nanodiscs from the second scaffold species – styrene maleic acid (SMA) is entirely 
detergent free.   
SMA lipid nanodiscs represent a new approach to lipid model preparation. This model 
is unique in its absence of detergent in all steps of nanodiscs preparation [341]. SMA is 
the hydrolyzed form of styrene-maleic anhydride copolymer synthesized by 
polymerization of styrene and maleic anhydride monomers (Figure 8). The method of 
SM anhydride preparation is a radical chain reaction which yields a wide distribution 
of molecular weights [348,349]. For lipid nanodisc preparation the range MW of 7.5- 10 
kDa is usually used [341]. This molecular weight variation also means that each new 
SMA batch needs to be optimized as it seems that lipid nanodiscs size varies with 
different SMA: lipid ratios. The process of SMA lipid nanodisc formation is still 
undergoing studies. For now, it has been observed that SMA insert itself into lipid 
bilayers which cause bilayer extension/swelling [350]. When SMA reach a critical 
concentration in the membrane, it will start to form lipid nanodiscs which will 
disassemble from lipid bilayer. This process seems to be in dynamic equilibrium as it 
has been observed that lipids from different nanodiscs population can come into close 




When SMA and MSP lipid nanodiscs are compared regarding suitability to use for 
α-synuclein: lipid interaction research, the SMA tends to surpass the MSP for two main 
reasons. The first reason is that MSP apolipoprotein, used for nanodiscs preparation, is 
structurally related to α-synuclein. The presence of another protein in the experiment 
could have a detrimental effect on results. The second reason is that the preparation of 






Figure 8: SMA Lipid nanodiscs. (A) The structure of the styrene-maleic acid polymer. (B) The 
MSP and SMA lipid nanodiscs structure. MSP lipid nanodiscs scaffold is formed by two 
molecules of MSP protein. Mutant forms of MSP of different lengths are used for exact size 
manipulation. Upper electron micrograph: MSP1E3 nanodiscs at a magnification of 180 000x 
[352]. SMA lipid nanodisc scaffold is formed by polymer species of styrene and maleic acid, 
usually in a ratio 3:1 or 2:1. Size is determined, besides other factors, by lipid concentration, 
the molecular weight of the SMA polymer and by what specific lipid species are present. 
Usually, another purification step (i.e., SEC chromatography) is needed to obtain homogenous 
nanodiscs size. Lower electron micrograph: SMA (3:1 ratio) lipid nanodiscs at a magnification 
of 120 000x [353]. Figure panel (B) was replicated with permission from [354]. (C) SMA lipid 
nanodiscs formation. (i) SMA binding to the membrane is determined by SMA concentration, 
salt concentration and by the charge of lipids in the bilayer [PX-]. (ii) After binding to the lipid 
bilayer, the SMA hydrophobic core spontaneously insert into the lipid bilayer. In this step, it is 
possible to observe an increase in the size of the vesicles. (iii) After SMA reaches a critical 
concentration in the lipid bilayer, the solubilized lipid nanodiscs will start to form. Figure (C) 







2 Aims of the thesis  
The transition of α-synuclein from inert monomers into toxic oligomers is a fascinating 
and complex process (see section 1.2 α-Synuclein). This transition is accompanied by a 
large restructuration of the protein, and it is affected by its lipid environment (see 
section 1.5 α-Synuclein and interaction with lipids). The lipids seem to be one of 
the important factor which strongly affects the transition of α-synuclein into oligomers 
and may play a role in disease etiology and toxic mechanisms. One of the lipid species 
which seems to affect α-synuclein fibrillation and toxicity behavior is cholesterol.   
Our overall aim was to improve the state of knowledge in lipidomics and to investigate 
how lipids may influence protein misfolding events and lead to fibrillation. This aim 
led us to pursue three goals which are connected to our overall ambition of 
understanding the role of the lipid environment in α-synuclein misfolding behavior.  
Our first goal was to investigate how the presence of cholesterol will affect 
oligomerization and fibrillation of α-synuclein. For this, we needed to establish 
cholesterol-containing lipid model systems that allowed us to track both interaction and 
fibrillation, and at the same time resolve effects that these events have on the protein 
conformation. We have prepared a novel lipid model: SMA lipid nanodiscs containing 
cholesterol. We have used biophysical techniques (HSQC NMR, SPR, and ThT 
fluorescence) to monitor the effect of cholesterol-containing nanodiscs on -synuclein 
conformation, its affinity towards lipid bilayer and oligomerization behaviour.   
In parallel, our second goal was to established lipidomics procedures involving efficient 
lipid isolation from limited cell sample for NMR studies. Initial work was done on 
Listeria innocua where we have improved standard methods for two-phase lipid 
isolation using dichloromethane and identified a new lyso-phospholipid species in 31P 
NMR spectra. We have also investigated the effect that lipid changes in a cell population 
have on the physical properties of the lipid bilayers.  
Our third goal was to improve the state of neurolipidomics knowledge so that potential 
lipid drivers of misfolding and oligomerization could be identified and quantified. We 
chose the SH-SY5Y neuroblastoma cell line, a much-used cellular model system for 
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studying PD, and we analyzed the whole cell and plasma membrane lipid composition 
by 31P NMR and LC-MS/MS. We streamlined and automated the LC-MS/MS analysis 





3 Summary of results  
3.1 α-Synuclein interaction with lipid bilayer is affected by the 
presence of cholesterol 
In Paper I we have investigated how cholesterol can affect α-synuclein affinity to lipid 
bilayer and its fibrillation. First, we used SPR to characterize the affinity of α-synuclein 
towards DOPC and DOPC:PE:PG (4:3:1) lipid vesicles with and without 30% 
cholesterol (w/w). Next, we prepared novel SMA lipid nanodiscs with the same lipid 
composition. We used these nanodiscs to measure changes in α-synuclein 
oligomerization rates in robust 384-well ThT fluorescence assay. We have then 
identified residue-specific apparent affinities of α-synuclein towards nanodiscs of the 
different lipid compositions using HSQC NMR.  
We observed that α-synuclein has an overall lower affinity towards lipid vesicles 
containing cholesterol independently of lipid composition. When fibrillation speed was 
tested, using lipid nanodiscs, we have observed a significant increase in oligomerization 
rate, again, for both lipid models containing cholesterol. Fibrillation started almost 
immediately, suggesting that cholesterol lipid nanodiscs can act in a manner similar to 
seeds. However, individual amino acid apparent affinities differ significantly for both 
models. For DOPC lipid nanodiscs, the addition of cholesterol seems to promote the 
interaction of the NAC core part of α-synuclein towards lipid nanodiscs. Meanwhile, 
the affinity of the rest of the protein (N-terminal and C-terminal) did not change 
significantly. When DOPC:PE:PG lipid nanodiscs were used we observed the opposite 
trend. The NAC part of α-synuclein was not affected by the presence of cholesterol. 
However, both N-terminal and C-terminal apparent affinities decreased. 
This observation suggests that different, lipid-dependent molecular mechanisms exist 
for α-synuclein binding to the lipid membrane.  These mechanisms can be annotated as 
“N-terminal pathway,” and “NAC-pathway.” Cholesterol seems to promote “NAC-
pathway” which leads to more volatile fibril formation. This different molecular 
mechanism could be crucial in vivo during pathological condition which can cause a 
local change in lipid composition.   
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3.2. Lipid composition and physical properties of prokaryote 
changes during the cell cycle 
In Paper II we established tools for efficient lipid isolation and identification of lipid 
species. We selected Listeria innocua as a suitable prokaryotic model. Cultures of L. 
innocua were synchronized by rifampicin after elongation but before cell division, in 
the C/D boundary, at the end of the exponential growth phase. We then used a revised 
two-phase method for lipid isolation using dichloromethane and triethylammonium 
ions. This new method provided longer stability of isolated lipids and improved yield 
(> 99%) compared to traditional methods [355]. We used 31P NMR to identify and 
quantify lipid species present in the samples. Furthermore, we have assigned lyso 
phospholipids species, including lyso-PG, and we proceed with LC-MS/MS 
identification of FA chains present for each headgroup.  
We observed the modulation of lipid composition which occurs between the B period 
and the C/D boundary in L. innocua.  Solid state (broad line) NMR revealed that this 
modulation in lipid composition during elongation of L. innocua represent a reduction 
in stored curvature membrane stress but without reduction to membrane fluidity. 
Curvature stress of the membrane is lowered by reduction of the PE fraction and fluidity 
is represented by an increase of PG (but not CL). Indeed, there seems to be coupling 
between membrane physical state and cell cycle of L. innocua. This study served as a 
proof-of-concept for further lipidomics experiments involving eukaryotic cells. It also 
suggests that the physical state of the membrane may be subject to functional 
modulations throughout the life-cycle of a cell. 
3.3. SH-SY5Y lipid compositions differ from average brain tissue  
In Paper III we used the method developed in Paper II for lipid isolation and 
identification of commonly used neuronal cell model SH-SY5Y. We have also adopted 
a method for plasma membrane isolation suitable for this cell line, and we have 
compared the composition of total cell lipid abundance with plasma membrane 
abundance. The lipid composition was analyzed by 31P NMR and by improved LC-




As part of this study, we developed an automated Matlab script for LC-MS/MS analysis 
of phospholipid samples. First, the script builds lipid fragmentation libraries based on 
data collected from literature and based on user input. The lipid search is based on a 
comparison of the MS2 spectrum with generated lipid libraries and score for each lipid 
species (based on a number of identified peaks and their intensity) is generated. The 
MS1 spectrum is then searched for identified lipid species in the observed retention time 
window, and an abundance of FA in each headgroup is calculated.   
The abundance of individual phospholipids differs from a general lipid model of the 
brain cell. Among other findings, there was a higher abundance of PC lipids reaching 
up to 60% of the total phospholipids. There was also a more pronounced presence of 
PG which was on the same level as PS (5%). The SM was observed mostly in the PM-
enriched sample, where they sum up until 18% of the total phospholipid content. The 
LC-MS/MS showed that the FA composition of PC is uniform in both whole cell and 
plasma membrane sample. The most abundant FA chains for PC was 18:1 and 16:0. FA 
abundance of PE has the highest variability from all the observed phospholipids. For 
the whole cell, the most abundant PE FA components were 18:1, 18:0 and 16:0.  
However, in the plasma membrane sample, there is a shift into FAs with longer chains 
and less saturation (like 20:1, 22:6 or 20:4). The difference between PE FA in the whole 
cell and the plasma membrane suggests a pronounced physiological role of PE in the 
membrane as storage component of curvature stress. 
These novel observations of the lipid composition of the SH-SY5Y neuronal cell line 
could lead us to new, more reliable and relevant lipid model for use in protein/lipid 
interaction research. Moreover, the study has increased the knowledge available 








4 General discussion  
4.1 Cholesterol role in α-synuclein:lipid interaction 
Cholesterol is one of the most abundant lipid species in eukaryotes. It can constitute up 
to 50% mass of plasma membrane in mammals and has a considerable effect on the 
physical properties of the membrane [356,357]. Cholesterol has also been linked to the 
progress of several neurodegenerative diseases including AD [288,358], Huntington’s 
disease [290] or Niemann-Pick type C [291,292]. However, the role of cholesterol in 
the interaction between α-synuclein and lipid bilayers is unclear as a consistent pattern 
of behavior has not been observed (see section 1.5.3 Cholesterol). We aimed to explore 
this interaction by monitoring α-synuclein affinity towards lipid bilayers of different 
compositions, both with and without cholesterol, and by monitoring changes in 
α-synuclein rates of fibrillation in the presence of these different lipid factors. First, we 
needed to established methods suitable for studying this particular lipid:protein 
interaction. For this, we had to choose and then establish a suitable lipid model system, 
design reliable ThT fluorescence assay and find a way to interpret peak broadening 
behavior of α-synuclein in solution NMR.  
4.1.1 SMA Lipid nanodiscs preparation is affected by lipid composition  
We searched for a suitable lipid model system which: (i) could contain cholesterol (ii) 
have enough long-term stability to be used in oligomerization experiments and (iii) have 
low molecular weight to maintain reasonably fast tumbling so that in-solution NMR 
experiments could be performed. This has been partially solved by using SMA lipid 
nanodisc (SMALN). However, SMALNs are still novel, and there are no reports of 
procedure for preparation of SMALN containing cholesterol available in the published 
literature. Our first practical goal was therefore to optimize the steps in SMALN 
preparation so that a sizeable population of cholesterol-containing lipid nanodiscs with 
narrow size distribution could be obtained. During this optimization, we have identified 
that SMALN formation is affected mainly by lipid composition.  
SMALN formation is affected by the presence of non-zwitterionic lipids. The anionic 
lipids (PG), conically shaped lipids (PE) and cholesterol all turned out to have an 
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adverse effect on lipid nanodiscs formation. DOPC lipid nanodiscs prepared by the 
standard protocol were formed quickly in a uniform manner only with 1% SMA present  
[341]. For DOPC with 30% cholesterol (w/w) we observed only an increase in the size 
of lipid vesicles, but nanodiscs did not seem to form (Paper I, Figure 1B). One solution 
to this problem was to increase the SMA concentration in the nanodiscs preparation 
protocol. However, a simple increase of SMA concentration also leads to a higher 
diversity of lipid nanodiscs sizes (Paper I, Figure 1C). To obtain a uniform population 
of lipid nanodiscs the procedure needed to be further modified. In final iteration of the 
protocol, the SMA polymer was added into the hydrated dispersion of lipids before the 
vesicles were formed. This meant that SMA was present during the cycles of freeze-
thawing and extrusion, and this seemingly helped to overcome the thermodynamic 
barrier in lipid nanodisc formation. With this new protocol, SMALN (both with and 
without cholesterol) were formed reliably (Paper I, Table 1).  
This behavior of nanodiscs formation is in agreement with the three-step model of SMA 
lipid nanodiscs formation (Figure 8) suggested by Scheidelaar, et al. [350]. It seems that 
after insertion into the bilayer, SMA can relieve packing stress in the vesicles by the 
formation of thermodynamically more stable nanodiscs. However, this is hindered by 
the presence of cholesterol and conical lipids, like PE, which are also able to lower 
stored curvature stress. We also observed that cholesterol-containing nanodiscs overall 
are larger (~30nm), than noncholesterol nanodiscs (~10 nm, Paper I, Figure 1D). It is 
not clear what causes this difference. It is possible that larger diameter is a consequence 
of different lipid packing in nanodiscs containing cholesterol. Nevertheless, SMALN 
proved to be extraordinary stable with uniform and constant size even two weeks after 
preparation.  
4.1.2 High throughput ThT fluorescence assay 
The ThT fluorescence assay is an established method which is regularly used to monitor 
the progress of amyloid protein fibrillation (see section 1.1.1 The oligomerization and 
seeding properties of amyloid-forming proteins). The ThT molecule is a molecular rotor 
which can interact with a cross β-sheet grove of growing amyloid fibrils. As long as 




efficient, and the fluorescence signal is very low. However, when ThT molecules 
interact with amyloid fibrils, the internal motion in the molecule is halted, and 
quenching is no longer efficient. ThT will then produce a strong fluorescence signal as 
a function of available sites on the growing fibril [22]. This behavior is used as the basis 
of a ThT fluorescence assay, an established assay, used to monitor amyloid fibril 
formation.  
However, even though this method is widely established, its use in α-synuclein research 
is limited for several reasons. The most important one is the time required for fibril 
formation. The fibrils of wild-type α-synuclein will, generally, start to form after 20 
hours of mechanical agitation. To be able to observe the whole fibrillation curve, an 
additional 20 hours are needed (Paper I, Figure 4B). In comparison – Aβ, is able to 
achieve fibrillation during 4 hours from the beginning of agitation [359].  This need for 
long–term agitation of α-synuclein means that small unilamellar lipid vesicles will not 
retain their structural properties and it is possible that after first 24 hours most of them 
will merge into large multilamellar vesicles or form lipid layer in the well, possibly 
affecting the results of the experiment [360].  
The fibrillation of α-synuclein can be speeded up by using external seeds. Seeds are 
various particles which can serve as a hydrophobic platform for initiation of 
oligomerization and subsequently fibril growth. In general, seeds are usually introduced 
as preformed α-synuclein oligomers or small particles of fibrils. However, using 
externally provided seeds introduce additional variability of the experiment, mainly 
because it is difficult to control the quality and consistency of the seed used [361]. 
α-Synuclein oligomerization is very sensitive to the presence of any contaminant which 
can serve as seeding agent [362]. This sensitivity also applies to small differences in 
agitation and other hard to control variables, which is known to cause high variability 
between samples.  
To overcome this problem, we have applied an adjusted version of the methodology of 
Afitska et al. [363]. By using 384 microwell plates, it is possible to do multiple repeats 
of experiments with minimal protein consumption. With more than >20 repeats per 
sample condition, it is possible to do a cumulative evaluation that increases reliability 
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and reproducibility of these experiments. In this approach, each well is evaluated only 
as positive or negative (in reference to negative control), and the cumulative percentage 
of positive wells can be plotted against the time (Paper I, Figure 4A). It is possible to 
use this cumulative curve to reconstruct fibrillation curve. While it is also possible to 
analyze the fluorescence intensity from each sample well independently (Paper I, Figure 
4C, 4D), the very high variability between samples necessitates a more significant 
number of repeats. From our experience usually more than 30 repeats for one 
experimental condition would be needed, with at least three biological replicates. 
Hence, the approach using cumulative, positive wells saves both time and material, 
while providing sufficient experimental repeatability (Paper I, Figure 4A). 
We also tested a new fluorescence dye - tetraphenylethene tethered with 
triphenylphosphonium (TPE-TPP), which is a structural analog of ThT [364]. TPE-TPP 
fluorescence yield is higher and can signal early fibrillation processes (Paper I, Figure 
2B). The motivation for using this compound was to be able to detect early oligomers 
forming in the presence and absence of lipid models systems. However, based on our 
results, TPE-TPP seems also to interact with lipid nanodiscs, which deemed this probe 
to be unsuitable for lipid:protein interaction experiments (Paper I, Supplementary 
Figure S2).   
4.1.3 α-Synuclein single amino acid affinity evaluation  
Solution-state NMR experiments monitoring α-synuclein in the presence of lipids 
present their own challenges. It has been previously reported that signals from most of 
the α-synuclein residues keep broadening beyond the limit of detection in the presence 
of lipids [276,365,366]. This happens due to efficient relaxation pathways related to 
molecular motions [276]. We expected that lipid nanodiscs would mitigate this issue 
and that most peaks in the fingerprint would be observable even in the presence of 
significant amounts of nanodiscs. However, this was not the case, and we observed line 
broadening beyond detection with an increasing amount of lipid nanodiscs (Paper I, 
Figure 5A).  
Still, we were able to extract some valuable information from collected data. First, it 




Those are residue which signal disappear first, with the lowest amount of lipids. These 
residues probably interact very strongly with a lipid bilayer (Paper I, Figure 5B). Indeed, 
all of these “invisible states” correspond with, among other, with non-perfect hexameric 
repeats KTKEGV and positively charged lysines, i.e. segments with high affinity to 
lipid environment [220,269,367]. Residues which did not interact with the lipid bilayer 
could also be observed directly. They are represented by peaks which did not broaden 
or move with increasing concentration of lipid nanodiscs (Paper I, Figure 5B).  Again, 
this is in line with other reports as most of these residues were localized to C-terminal, 
which does not seem to interact with the lipid bilayer [213,276]. 
The rest of these residues are intermediately responsive to the presence of the nanodiscs, 
and these could be evaluated using the methodology presented by Shortridge et al. 
[368]. Changes in peak area with increasing concentration lipids can be fitted to a 
binding model (Paper I, Figure 6C) and an affinity constant (KD) can be calculated for 
each residue. However, this affinity constant may also contain information about other 
possible molecular relaxation modes, like the interaction between two molecules of 
α-synuclein or broadening effects from the dynamic exchange of α-synuclein between 
the nanodisc and the solvent. Therefore, we treat this as an apparent affinity constant 
(aKD), which reflect all changes caused by the presence of the lipid environment. 
However, it does not have to be only due to the direct binding of residue to the lipids.  
4.1.4 Cholesterol and α-synuclein interaction is driven by lipid environment 
Cholesterol seems to have a very complex role in α-synuclein behavior in a lipid 
environment. First, we have observed that cholesterol inhibits binding of α-synuclein 
with lipid vesicles (Paper I, Figure 3). This effect was similar for both lipid models 
(DOPC and DOPC:PE:PG), and the presence of 30% cholesterol caused a doubling of 
KD in both cases. However, the presence of PE and PG has a more significant effect on 
α-synuclein than the presence of cholesterol. The KD of α-synuclein towards 
DOPC:PE:PG vesicles containing cholesterol was still four-fold lower than for DOPC 
vesicles without cholesterol. This suggests that tighter packing of lipids, caused by the 
presence of cholesterol, has a negative impact on the α-synuclein bilayer interaction. 
However, the presence of anionic lipids (PG) and lipids able to store curvature stress 
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(PE) is a stronger determinant of α-synuclein affinity, and electrostatic interaction is the 
dominating force in the binding process. These findings are consistent with the previous 
reports of the adverse effect of cholesterol on α-synuclein binding [307].   
Our next question was: What is the role of cholesterol in α-synuclein fibrillation? We 
explored this by setting up fibrillation assays monitored by ThT fluorescence in the 
presence and absence of lipid nanodiscs, with and without cholesterol included (Paper 
I, Figure 4). We observed that lipid nanodiscs lacking cholesterol cause a delay in 
α-synuclein fibrillation. For both lipid models, there was an almost three-fold increase 
in the lag-time, but no changes in fibrillation rate (see section 1.1.1 The oligomerization 
and seeding properties of amyloid-forming proteins). This suggests that the protein 
interaction with lipid environment caused an efficient decrease of free monomeric 
α-synuclein population. This results in slower oligomer formation and slower fibril 
formation [269,369]. However, when the lipid nanodiscs containing 30% cholesterol 
were present in the experiments, we observed a rapid increase in fibrillation processes 
- both lag time and fibrillation rate had been affected. It seems that lipid nanodiscs 
containing cholesterol could serve as a seeding agent and they can initiate almost 
immediate fibrillation, reducing lag time from 20 hours to less than an hour. Increase in 
fibrillation rate ratio shows that lipid nanodiscs containing cholesterol, not only act as 
a seed, but they can actively promote further growth of amyloid fibrils. Theories about 
the possible mechanism of actions, including molecular crowding [370] or aligning of 
NAC sequences [371] are further discussed in Paper I.  
Solution NMR revealed that the mechanism of α-synuclein interaction with lipid bilayer 
containing cholesterol is defined by lipid composition. For the DOPC model, we could 
see that binding towards lipid is promoted mostly by NAC terminal (Paper I, Figure 
6A). For DOPC:PE:PG model the situation is different and the presence of cholesterol 
is affecting C-terminal and N-terminal of protein (Paper I, Figure 6B). However, in this 
case, it is repulsion towards lipid bilayer. Cholesterol rich-sites seems to provide NAC-
supported binding mode which is fundamentally different from standard N-terminal 




modes can explain some discrepancy in the literature regarding the role of cholesterol 
in α-synuclein:lipid interaction.  
Taken together our experiment shows that cholesterol inhibits binding of α-synuclein 
towards lipid bilayer and that it serves as a seeding agent in lipid nanodiscs, promoting 
faster fibrillation processes. This effect is seemingly independent of the other lipids 
present. The result is intriguing, as it is suggestive binding modes that are not reflected 
in standard affinity measurements. However, when examined by residue-specific 
HSQC NMR, we could see the contrasting difference of α-synuclein behavior. This 
difference can be explained by the possible existence of two-binding modes, a 
NAC-supported and an N-terminal supported binding mode.  
The N-terminal binding is dominating mode in the presence of anionic lipids, and it 
leads to typical α-synuclein binding towards lipid bilayer which ends with the formation 
of α-helix. Further oligomerization is, generally slower because monomeric α-synuclein 
is localized on lipid bilayer and it is not available for oligomerization. The NAC binding 
mode is dominating in the presence of lipid bilayers containing cholesterol. In this case, 
α-synuclein binds towards lipid bilayer preferably by NAC segment. This could lead to 
different oligomerization pathway, which results in rapid oligomerization and 
fibrillation processes. The NAC binding could become dominant in case of a local 
increase of cholesterol concentration in neuronal cells.   
4.2 Prokaryote modulate its lipid composition during the cell 
cycle  
In parallel, we set out to established and improve the lipidomics methods available in 
our laboratory. The methods established should be able to discern changes in lipid 
profiles and assess whether these changes translated into modulations in physical 
properties of the membrane. Bacteria are, in general, easier to culture and have simpler 
lipidomes. Therefore, we aligned this goal with the investigation of the lipid content 
changes of Gram-positive bacteria during its life cycle. For this work, we selected the 
bacterial strain Listeria innocua NCTC 11288, mainly because it is biologically similar 
to pathogenic L. monocytogenes [372,373] and because it does not sporulate under 
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stress, unlike another commonly used Gram-positive model, B. subtilis. It has also been 
shown previously that Gram-negative E. Coli modulates its lipid composition [370]. 
This led us to a search for a similar trend in Gram-positive bacteria. 
We used the bacteriostatic rifampicin to synchronize bacterial culture at the C/D 
boundary, just before bacterial division, which was confirmed by measuring the size of 
the cell (Paper II, Figure 1).  Then, we implemented a new modification of the two-
phase method of lipid isolation which addresses some shortcomings of other traditional 
methods [374]. In order to maximize lipid extraction efficiency, we implemented three 
changes relative to traditional methods: (i) We used triethylammonium ions (TEAC) as 
a counter-ion for lipid extraction, which is soluble in organic solvents and helps to 
mitigate migration of phospholipid species into the organic phase. (ii) Methanol, used 
in traditional lipid isolation methods, was replaced with dichloromethane to minimize 
lipid degradation. (iii)  Before the two-phase isolation procedure, we washed the 
freeze-dried cell samples with a mixture of organic solvents (dichloromethane, 
methanol and TEAC). The combination of these measures yielded an isolation 
efficiency of >99% of total phospholipids (Paper II, Figure S3).  
We observed significant modulation of lipid composition in L. innocua between C/D 
period boundary and unsynchronized culture. Most notably was the change in PE, CL 
and PG content (Paper II, Figure 2). We then investigated the phase behavior of the 
lipid system with the same composition as unsynchronized L. innocua and culture in 
C/D boundary using solid state (broad line) 31P NMR (Paper II, Figure S7-S10). We 
observed that these differences were significant enough to represent changes in the 
physical properties of the lipid membranes as the bacterial moved into the C/D 
boundary. The reduction of PE content led to a reduction in stored curvature stress of 
the membrane. This reduction of curvature stress was compensated for by an increase 
in the PG content which provides an increased fluidity. There was no increase in CL 
content so the increase in PG can be interpreted as a regulation mechanism to maintain 
sufficient fluidity of the membrane. The observed changes in physical membrane 




The lipid changes during prokaryotic cell cycle present a question whenever also 
mitochondria do modulate its lipid content throughout its cell cycle and if so how this 
can affect potential interaction between mitochondria and α-synuclein. This result, as 
well as other works [376,377], suggests that the lipidome and the resulting properties 
of the cell membrane may vary significantly depending on the state of the cell. 
4.3 Lipid composition of SH-SY5Y  
Lastly, we have applied methods developed in Paper II to pursue our third goal: the 
lipidomics analysis of a neuroblastoma cell line – SH-SY5Y. This cell line is a 
frequently chosen model when studying neurodegenerative disease, including PD 
[378,379]. Lipids are implicated pathological factor in PD pathogenesis; however, so 
far, there is only one a phospholipidomics analysis of this cell model, using only 31P 
NMR [380]. We have investigated the phospholipid content of a whole cell and plasma 
membrane fraction of SH-SY5Y using 31P NMR and LC-MS/MS automated analysis. 
An important part of this study was focused on developing LC-MS/MS automated fatty 
analysis. With the help of 31P NMR, we have identified the phospholipid headgroups 
present in the sample and determined the relative amounts of each associated lipid 
species present. We have then used LC-MS/MS for detailed FA analysis. However, to 
be able to analyze a large amount of data obtained we needed to develop a suitable tool. 
For this, Matlab 2017b was used to build a script which can: (i) build lipid libraries of 
predicted fragmentations, based on information collected from literature, (ii) assign the 
signals in collected MS2 spectra to their corresponding precursor lipid and (iii) analyze 
the FA chain content in the MS1 chromatogram for each phospholipid headgroup (Paper 
III, Figure 2). This script, named the LipMat script, is available online on GitHub: 
https://github.com/MarJakubec/LipMat. 
We observed several differences between a whole brain lipid content (See the section: 
1.6 Neurolipidomics) and SH-SY5Y. The most striking one was the much higher PC 
(55%), and lower PE abundance (18%, Paper III, Figure 1) found. Also, SM content 
was much lower making it less abundant species than is generally observed in brain 
lipid analysis. SM in whole cell sample comprises 3% of the total lipids. However, when 
the PM was analyzed, it was the third most abundant lipid species with 18% of 
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abundance. These values reflect that most of the mass of SM in SH-SY5Y is present in 
the PM (Paper III, Figure 3). FA analysis showed that PC had the most uniform FA 
distribution (~75% of all PC lipids was composed of only one of the four types of FA 
chains detected). PE FAs were seemingly also non-variable in the same manner in a 
whole cell sample, and almost 90% of observed PE lipid species had one of the three 
detected FA. However, in the PM fraction, we observed for PE a much broader variety 
of FA chains that also contained long unsaturated chains (22:6 and 20:4). This FA 
distribution suggests that PE in the PM can act as one of the primary stores of curvature 
stress. Meanwhile, in the whole-cell sample, this role is performed by other conical lipid 
species with longer FA chains, like PG.  
It is clear that the lipid composition of SH-SY5Y cell is different from generic models 
of cell lipid compositions, nor is it similar to a mean of brain lipid composition. This 
has to be taken into account in any further research which are focused on the role of 






5 Concluding remarks and future perspectives  
In this thesis, we have presented our current work in the amyloid protein:lipid 
interaction field. In Paper I we worked on establishing and improving several methods 
used to study amyloid protein and lipid interaction, which included SMA lipid 
nanodiscs, fibrillization assays and determination of residue specific apparent affinities 
by NMR. We applied these methods in the investigation of the role of cholesterol in 
α-synuclein affinity towards lipid bilayer and its fibrillation, and managed to link local 
affinities within the -synuclein to the prescence of cholesterol and promotion of 
fibrillation. In Paper II we established a suite of lipidomics tools in the lab where the 
project took place, where no such tools existed beforehand. In some cases, it has also 
been possible to improve on current methodologies in the field, including reaching high 
lipid extraction efficiencies and better control of enzymatic lipid degradation. These 
tools have been tested on prokaryotic L. innocua. In Paper III we have used these tools 
for lipidomics analysis of SH-SY5Y neuroblastoma cell line, and we have developed 
an automated Matlab script for mass spectrometry analysis of FA chain abundance.  
Taken together we are left with more questions than answers. Further research will aim 
to elucidate some of these questions, including: Is two-mode binding of α-synuclein 
towards the lipid membrane biologically relevant? If prokaryotic cells modulate its lipid 
content during cell growth does the same modulation happens in mitochondria and 
could these mitochondrial lipid changes affect the progress of PD? Does the lipid 
composition of SH-SY5Y cell correspond to a standard or abnormal neuronal cell? 
Which specific lipid species do α-synuclein come into contact with in neurons? What 
is the subcellular SH-SY5Y lipid distribution? 
Our next experimental work will aim to answer some of these questions. We are 
currently working on a further improved PM isolation protocol which will allow us to 
obtain higher lipid mass and, hopefully, to observe also minor phospholipid species by 
31P NMR. We are also currently working on a suitable protocol which allows us 
simultaneously to perform phospholipidomics analysis and quantitative analysis of 
cholesterol in different compartments of SH-SY5Y cells. This new lipidomics 
information can then be used to build suitable lipid models which can be used for 
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relevant in-vitro testing of αsynuclein behavior in different lipid environment. It may 
also be possible to prepare nanodisc directly from live cell membranes instead of 
artificial vesciles, use these in oligomerization assays and in this way link further 
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Evidence that Listeria innocua 
modulates its membrane’s stored 
curvature elastic stress, but not 
fluidity, through the cell cycle
Samuel Furse1, Martin Jakubec1, Frode Rise3, Huw E. Williams2, Catherine E. D. Rees4 & 
Øyvind Halskau1
This paper reports that the abundances of endogenous cardiolipin and phosphatidylethanolamine 
halve during elongation of the Gram-positive bacterium Listeria innocua. The lyotropic phase behaviour 
of model lipid systems that describe these modulations in lipid composition indicate that the average 
stored curvature elastic stress of the membrane is reduced on elongation of the cell, while the fluidity 
appears to be maintained. These findings suggest that phospholipid metabolism is linked to the cell 
cycle and that changes in membrane composition can facilitate passage to the succeding stage of the 
cell cycle. This therefore suggests a means by which bacteria can manage the physical properties of their 
membranes through the cell cycle.
The bacterial cell cycle is an example of binary fission that is typically both rapid and reliable. It is characterised by 
periods known as B, C and D1–4. The B period represents the phase between division and the initiation of replica-
tion, whereas the C period (sometimes called the replication phase) represents the phase in which the nucleolus 
is replicated and in which the bacterium reaches its mature size. The D period is that between the replication 
of the DNA and fission of the cell envelope. The B, C and D periods can therefore considered analogous to the 
eukaryotic G1, S and G2 phases, respectively. However, despite considerable research, little is understood about 
how progress from the B to D periods is controlled.
In Eukaryotes it is known that the cell cycle is controlled through the interaction of cyclin and 
cyclin-dependent kinases5–7. However, to date there is no evidence for the presence of homologues of cyclin in 
bacteria. Furthermore, studies of Gram-negative species have been unable to produce evidence for regulation 
of cell division either through changes in gene expression8 or changes in the concentration of the proteins that 
comprise the divisome9, 10. Existing models for the control of bacterial cell division allow for several possible 
mechanisms. One is based on regulation of increase in cell size (the size adder theory11–13). Another is that cell 
size is regulated in advance of division, possibly through dilution of a ‘timekeeper’ protein, though the mech-
anism underlying this model is not known13, 14 and it is not clear whether such proteins would control, or are 
rate-limiting, with respect to the cell cycle. There are also hints that cell structure is a determinant in controlling 
the binary fission in bacteria15. In principle, control of progress through the cell cycle through changes in cell 
structure could be based on both structural proteins and lipids, but knowledge of the role of lipids in this is 
lacking.
Recent work on lipids and their metabolism in the Gram-positive bacterium Bacillus subtilis has revealed a 
link between the synthesis of phospholipids and the divisome. This evidence suggests that de novo synthesised 
lipids are produced at the septum during fission16. Furthermore, there is evidence for an overall change in the 
lipid profile of the Gram-negative Escherichia coli through its cell cycle15. The latter work showed that the abun-
dance of curvature-forming cardiolipin (CL) falls whilst that of the bilayer-forming phosphatidylglycerol (PG) 
increased on elongation of the cell at the C/D boundary. Evidence from biophysical studies conducted over the 
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last half-century shows that modulation of lipid composition can have a considerable impact on the lyotropic 
phase behaviour of lipid systems17, 18. For example, an increase in the fraction size of phosphatidylethanolamine 
(PE) increases the propensity of a lipid system to assemble into curved phases rather than bilayer-like ones19, 20. 
This is known as increasing stored curvature elastic stress, SCES21.
Determining the relationship between lipid composition and phase behaviour complements the interpre-
tation of lipid profiling studies. Data from studies of the phase behaviour of lipids suggest that the increase in 
abundance of a bilayer-forming lipid and the reduction in abundance of a non-bilayer forming lipid that occurs 
in E. coli on elongation, reduces SCES22–25. This is consistent with the changes in morphology of the cell during 
elongation because average curvature is lower in elongated cells and the evidence that the location of the Z-ring 
may be determined by cell membrane geometry26–28. This led us to the hypothesis that the production and shape 
of the cell envelope is involved in controlling the cell cycle of bacteria. If correct, this hypothesis implies that the 
topology of the plasma membrane and thus the physical properties of its lipids play a significant role in progress 
through the cell cycle in bacteria.
In order to investigate whether modulation of lipid composition through the cell cycle is a general feature of 
bacteria we measured global changes in the lipid profile of a bacterium that is evolutionarily distinct from E. coli. 
Listeria innocua NCTC 11288 was chosen because, unlike the commonly studied model Gram-positive B. subtilis, 
it does not sporulate under stress. L. innocua also has clinical relevance29, due to its biological similarity to the 
pathogen L. monocytogenes30, 31.
Cultures of L. innocua in the exponential phase were stopped after elongation but before cell division (around 
the C/D period boundary) with the bacteriostatic antibiotic rifampicin (RIF) using an adapted15 version of an 
established method32–34. The lipid fractions (LF) were isolated from freeze-dried, pelleted cultures whose cell 
walls had been thoroughly digested. The LFs were profiled using a combination of solution phase 31P NMR and 
HR-MS/MS35. The relationship between changes in lipid composition and membrane morphology observed in 
L. innocua was investigated using broad line 31P NMR to characterise the phase behaviour of model systems that 
corresponded to the lipid compositions observed.
Results
Culture growth and synchronisation. Cultures of L. innocua NCTC 11288 were grown in tryptic soya 
broth at 37 °C and the growth phase synchronised using RIF15. A growth curve was used to identify the appropri-
ate point to administer the arrest drug (determined empirically to be 240 min (Fig. 1).
The experimental steps for preparation of samples and collection of profiling data are shown in Fig. S1. Based 
on their size distribution the synchrony of the untreated exponentially growing cultures was determined to be 
>80% (and the cell size analysis suggested that these were predominantly in the B period) (Fig. 1). The cell 
size was measured using cells stained with Nile Red observed using fluorescence microscopy. These data were 
used to establish the efficacy of RIF in arresting and holding cells at the C/D boundary and cells from such 
cultures were found to be significantly longer (mean = 1.92 µm, ± 0.44 µm) than those in the untreated sam-
ples (mean = 1.34 µm, ± 0.29), with only 6.7% being as short or shorter than those seen to predominate in the 
untreated samples (t-test, p =  < 0.01). Based on these results the untreated samples were taken to be representa-
tive of cells in the B period, and the RIF-treated samples representative of cells at the C/D boundary.
We took several steps in order to avoid chemical and enzymatic degradation of lipids. After centrifugation 
cells were resuspended in PBS to suppress PI-PLC activity36, and a mixture of lipase inhibitors was added to sup-
press the activity of these enzymes ex vivo15, 35. A mixture of mutanolysin37, lysozyme and RNAase was added to 
digest the cell wall and thus maximise access to the lipid fraction38.
Possible contamination of the cultures was checked for by inspecting the 1H spectrum of the FA fraction but 
none was found (that of Listeria ssp.39–42 is distinct from other commonplace bacteria, such as E. coli43–46. See 
Preparation of fatty acid isolates in Experimental Methods, and Fig. S2).
Isolation of the lipid fraction. The LFs were extracted using a two-step method that was designed to 
address the apparent short-comings of traditional methods47 (see Experimental for details). Triethylammonium 
ions were used to provide a counter-ion that is soluble in organic solvents and thus favours migration of phos-
pholipid species into the organic phase. Dichloromethane was used in place of chloroform in order to mini-
mise chemical degradation of lipid species47. Lastly, in order to maximise the extraction efficacy, the freeze-dried 
free-flowing powdered cellular matter was washed in a mixture of organic solvents (dichloromethane/methanol/
triethylammonium chloride, 3:1:0.0005, v/v/w) before being dispersed in water and methanol, and extracted with 
dichloromethane. In order to test the effectiveness of this procedure, the aqueous fraction and precipitate from 
the isolation of the LF were freeze-dried and treated with strong acid (5% H2SO4) in order to hydrolyse any FA 
ester bonds and thus release any remaining FAs. The amount of FA found is treated as proportional to the mass of 
the lipid not collected during the isolation. The data from these measurements (1H NMR, see Experimental and 
Fig. S3) suggest that the procedure used in this study extracted >99% of the LF. This compares favourably with 
around 85% for the original Bligh & Dyer method48.
Profiling of the lipid fraction. The LFs were profiled using a combination of solution phase 31P NMR 
and HRMS/MS35. 31P NMR was used for quantification because it allows non-destructive and unambiguous 
high-resolution spectroscopy of the organically-soluble phosphorus-containing molecular species present. 
Lysylated lipids have not been profiled using 31P NMR before and so the shifts of lysyl-dioleoyl phosphatidylg-
lycerol (lysyl-DOPG) were determined (Fig. S4). Representative spectra of the lipid profiling and the relative 
abundance of lipids in the B period and at the C/D boundary are shown in Fig. 2A. A combination of high reso-
lution and tandem mass spectrometry were used to identify both the head groups present and the range of lipid 
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Figure 1. Identification of growth phases and image analysis of cultures. Panel A, Growth curve for L. innocua 
NCTC 11288 grown in TSB at 37 °C (n = 3 independent experimental measurements per point). The lag phase lasted 
for approximately 150 min (------); exponential phase (untreated cultures) began at about 150 min and by 400 min 
the cells were in the stationary phase. In cultures treated with RIF, stationary phase was induced immediately 
although some growth was still detected for ~120 min. Samples in panels B and C (untreated controls) were collected 
after 240 and 360 min and sample in panel C was collected 240 min after RIF administration (at 480 min). Panels 
B–D show light and fluorescence micrographs of L. innocua; for fluorescent imaging samples were stained with Nile 
red (1000 × magnification; scale bar = 1 µm). A graph of the distribution of cell lengths is shown for each sample with 
Gaussian distribution (red line). Data represents 180–200 cells from at least three images from four independent 
cultivations. The Box plots show medians, 50% of data in the range (box), non-outliers range (whiskers) and outliers 
(circles and stars). Sample B is representative of cells in exponential phase growth (240 min after inoculation) with 
the majority of cells appearing to be in the B period (>80% synchrony; mean = 1.34 µm, ± 0.29 µm). Sample C is 
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isoforms present (Table S1 shows the lipid abundance and isoform profiles. Representative lipid fragmentation is 
shown in Fig. S5).
These data show that the abundance of both cardiolipin (CL) and phosphatidylethanolamine (PE) fall signifi-
cantly between the B period and at the C/D period boundary. The fraction size of CL falls by around 40% whereas 
that of PE falls by about 60%. The absolute value for the abundance of PG varies between cultures, but does not 
appear to be statistically significant. This is perhaps surprising in view of the significant decreases in both CL and 
PE, however it is not clear why this should be. It seems unlikely that this is due to lysylation as the abundance of 
lysyl-PG is also not statistically significant, despite notable shifts in the absolute values. The abundance of major 
structural lipids CL and PE does not change substantially between cultures at the beginning and end of the expo-
nential phase, while PG changes to some extent (Table S1). Unlike E. coli, the age of cultures of Listeria does not 
appear to correlate with changes in its lipid profile.
Profiling of the fatty acid residues (FARs) of the total lipid fraction did not indicate a difference in the FA 
profile between periods, suggesting that FA production is not linked to the cell cycle in this organism (Fig. S6). 
These data therefore indicate that although the lipid profile changes through the cell cycle of L. innocua it does 
not change with the age of rapidly-dividing cells. Furthermore, cell-cycle dependent changes are restricted to the 
head groups of the major structural species. Taken together, these data suggest that synthesis of the principal head 
groups in particular is linked to the expansion of the membrane during the B and C periods.
These data (Fig. 2B, Table S1) are consistent with the published evidence that the bulk of the Listeria LF com-
prises PE49 and lysyl-derivatives of PG and CL50, but is at odds with reports in which PE appears not to have been 
found39, 50. Conversely, phosphatidylinositol (PI) was not detected in any sample in this study despite the presence 
of several PLC inhibitors, contrasting with reports of the presence of PI in a closely-related strain of Listeria42, 51. 
We note that the lipid profile of biological samples can be influenced by myriad factors, including the medium 
used, how cultures are incubated and handled, how the LF is isolated, handled and profiled, and even the activity 
of endogenous lipases ex vivo47.
Lyotropic phase behaviour of model membrane systems. The evidence for modulations in the abun-
dance of CL and PE during cell elongation raises the question of whether membrane properties change with these 
changes in composition. Studies of the phase behaviour of PG, PE and CL over the last half-century have shown 
that they have distinct properties. PE’s spontaneous curvature is negative19, 52–54, as is CL’s but only in the presence 
of a high concentration of divalent cations23, 55, 56. PG’s phase behaviour is dominated by lamellar phases, suggest-
ing that its spontaneous curvature is negligible24, 25, 57–59. Modulation of the abundance of PE and CL (with a low 
concentration of divalent cations) is therefore a change in the abundance of two major structural lipids with con-
trasting spontaneous curvature. That these changes in abundance occur through the cell cycle therefore suggests 
that the stored curvature elastic stress of the membrane also changes through the cell cycle. We investigated this 
by modelling the behaviour of two-lipid mixtures using broad line 31P NMR.
Model systems comprised the di-oleoyl isoforms of PG and PE (DOPG and DOPE), and tetra-oleoyl isoform 
of CL (TOCL). Temperature scans of the individual lipids revealed the established behaviour, i.e. systems com-
prising either TOCL or DOPG showed fluid lamellar (Lα) phase over the temperature range studied (Fig. S7A,B), 
with DOPE undergoing a transition from Lα to inverse hexagonal (HII) only above 273 K (Fig. S7C).
Mixtures of DOPG with TOCL show a strong preference for Lα, even at relatively low temperatures (273 K, 
Fig. 3A; Fig. S8A–C), suggesting that both lipids confer fluidity on systems in which they are present. The Lα 
phase also dominates across most of the concentration range in mixtures of DOPG and DOPE at 273 K (Fig. 3B), 
but higher temperatures favour curved phases (e.g. 310 K, Fig. 3C; Fig. S9). These data indicate that PE confers 
stored curvature elastic stress on PG systems. In particular, a reduction in PE from 36% to 18%, similar to that on 
elongation of L. innocua, reduces the ability of that system to form curved phases, suggesting a significant reduc-
tion in SCES. The Lα dominates in mixtures of DOPE with TOCL where the concentration of DOPE is below 
50% (273 K, Fig. 3D). This also indicates the preference for lamellar phase(s) by TOCL at low concentrations of 
divalent cations (Fig. S10A), and curved phases by PE (Fig. S10C). Thus, although the fraction of CL shrinks on 
elongation of L. innocua, the increase in that of the DOPG ensures that the reduction in the abundance of PE 
reduces SCES.
However, it appears that doping DOPE with rather small quantities of DOPG (22-13:1, 4.3-7.1%) or TOCL 
(~36-12:1, 2.7-7.7%) allows the formation of curved phases at 273 K, particularly the HII phase (Figs 3B and S9, 
and Figs 3D and S10). Importantly, the phase transition from fluid lamellar to the HII phase occurs in DOPE 
around 10 K higher than this, at ∼ 281K60. This suggests that the presence of small quantities of these lipids can 
relieve the packing stress of the HII phase.
Data from a mixture of lysyl-DOPG with TOCL suggest that lysyl-DOPG has similar fluid properties to 
DOPG (Fig. S8C and D) but does not reduce the packing stress of DOPE systems as DOPG does (Fig. S9E and F). 
Notably, the behaviour of DOPE:lysyl-DOPG (22:1, Fig. S9F) is very similar to that of pure DOPE (Fig. S7C), and 
both are distinct from DOPE:DOPG (22:1, Fig. S9E). In the latter, the less abundant lipid appears to reduce the 
packing stress of the inverse hexagonal phase. This suggests that the role of lysyl-DOPG in the membrane differs 
from that of PG and may be related more to modulations in SCES and/or lipid packing than to fluidity.
representative of cells at the end of the exponential phase (360 min after inoculation) and represents the B period of 
older cultures (>80% synchrony; mean = 1.22 µm, ±0.26 µm). Sample D is representative of cells arrested at the C/D 
boundary by RIF (80-90% synchrony; mean = 1.92 µm, ±0.44 µm). Only 6.7% of cells in the C/D boundary samples 
are as short or shorter than those seen to predominate in the untreated samples (t-test, p =  < 0.01).
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Discussion
The evidence from this study indicates that the modulations in lipid composition in L. innocua that occur between 
the B period and C/D boundary are statistically significant. The behaviour of model systems suggests that the 
modulations in lipid composition on elongation of L. innocua represent a reduction in the SCES of the membrane 
(observed as a reduction in size of PE fraction, Fig. 3B) but without a reduction in its fluidity (with an increase in 
PG and despite a decrease in CL; Fig. 3A and D). This suggests that the physical properties of the membrane are 
linked to the cell cycle.
The behaviour of model lipid systems observed in this study supports the conclusion that changes in lipid 
composition favour changes in morphology of the membrane on a cellular scale. Comparison of the lipid profile 
and distribution between different rod-shaped bacteria (such as E. coli and B. subtilis) and between rod-shaped 
and spherical bacteria (such as Staphylococcus aureus) are therefore of interest in understanding the cellular struc-
ture of prokaryotes. However, comprehensive cell-cycle-based lipid profiling of prokaryotes is lacking at present. 
What is known, is that E. coli and B. subtilis have very different distributions of lipids in their membranes, which 
Figure 2. Profiling of the phospholipids in L. innocua NCTC 11288 at different stages of the cell cycle. 
Panel A shows representative 31P NMR spectra of the lipid fraction collected from B period cultures and 
cultures at the boundary of the C and D periods. The relative area of the integrations of the appropriate 
resonance(s) were taken as a fraction of the total integrations for each spectrum and used to generate the 
fraction size given for each sample. The shift of phosphate mono-ester-containing lipids such as PA, is pH 
dependent. PE exhibits several resonances due to concentration and pH-dependent solvent interactions15, 78. 
Panel B shows the abundance of lipids in the B period and at the C/D period boundary from cells collected 
in the exponential phase. Asterisks mark the head groups (CL, PE) for which the difference in abundance is 
considerable (when comparing standard deviations, n = 5 independent samples profiled using quantitative 31P 
NMR). CL, cardiolipin; lyso-PA, lyso-phosphatidic acid; lyso-PG, lyso-phosphatidylglycerol; lysyl-CL, lysyl-
cardiolipin; lysyl-PG, lysyl-phosphatidylglycerol; PA, phosphatidic acid, PE, phosphatidylethanolamine; PG, 
phosphatidylglycerol; PS, phosphatidylserine.
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are linked to differences in proteins associated with cell division, and therefore cell shape is not expected to be the 
only factor that determines this change61.
We note that the modulations in lipid composition of the Gram-positive L. innocua are analogous to those 
reported for the Gram-negative bacterium, E. coli. In the latter organism, the abundance of the bilayer-forming 
Figure 3. Stacked spectra showing the phase behaviour of two-lipid systems as a function of lipid head group 
composition. (A), DOPG/TOCL mixtures at 273 K; (B), DOPE/DOPG at 273 K; (C), DOPE/DOPG at 310 K; 
(D), DOPE/TOCL scan at 273 K. The 36:64 and 18:82 mixtures of DOPE:DOPG represent the ratio of these 
two lipids in the B period and at the C/D boundary, respectively. DOPG, dioleoylphosphatidylglycerol; TOCL, 
tetraoleoylcardiolipin; DOPE, phosphatidylethanolamine. Full temperature scans of each lipid mixture can be 
found in Figs S8–10.
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PG increases during its elongation (from ~1:22 to ~1:16 against PE), with a reduction in the abundance of CL 
(from ~1:16 to ~1:36 against PE)15. Physical data from the present study suggest that there is also a reduction in 
the tendency to form the hexagonal phase (lower SCES) in E. coli, without a reduction in fluidity on progression 
from the B period to the C/D boundary. This indicates that E. coli has adopted the same pattern with respect to 
modulation of lyotropic phase behaviour between the B period and C/D boundary as seen in L. innocua.
This remarkable similarity between two bacteria that are quite separate in evolutionary terms raises the ques-
tion of whether such modulations are important for the structure of rod-like cells in general. However, it is not 
clear from these data whether this trend is limited to cells with a cell wall; further work is required to establish 
what effects modulations in lipid composition have in other cell types.
It is appealing to speculate what further effects the modulations in lipid composition may have on membrane 
properties. The folding and function of proteins of both bacterial and eukaryotic origin have been shown to 
be sensitive to lipid membrane composition62–64, and to SCES and packing defects65, 66. This coupling between 
the membrane’s physical state and the proteins’ folding can also manifest itself in problematic rather than func-
tional ways. For instance, there is evidence that charged head groups such as those of PG and phosphatidylser-
ine enhance the membrane binding and mis-folding behaviour of α-Synuclein67, and that packing defects are 
involved in promoting mis-folding of a protein linked to Parkinson’s disease68, 69. Particular constellations of 
ganglioside and cholesterol have also been proposed to promote both membrane binding and mis-folding in 
α-Synuclein and β-amyloid peptide70.
It is clear that further work is required to fully characterise the relationship between lipid composition and 
distribution in bacteria71 and in eukaryotic72 cells. Data such as that acquired in this study indicate the extents to 
which the lipid composition and phase behaviour vary with the cell cycle. These alterations may in turn have an 
impact on the structural and functional properties of the membrane they comprise.
Experimental Methods
Reagents and chemicals. Growth medium, solvents and fine chemicals were purchased from SigmaAldrich 
(Gillingham, Dorset, UK) and used without purification. PhosSTOP tablets were purchased from Roche 
(Welwyn, Hertfordshire, UK) and stored at 4 °C. Purified lipids were purchased from Avanti Polar lipids Inc. 
(Alabaster, Alamaba, US) and used without further purification.
Cultivation of L. innocua. The growth kinetics of this bacterium in tryptic soya broth (TSB) was char-
acterised over 24 h (Fig. 1). The preparation of one set (n = 1) of cultures is described. Each sample comprised 
three cultures in order to ensure that enough material was produced and to account for differences between 
populations. Thus for each biological replicate, 3 × 3 × 1 L cultures were grown in unmodified TSB that had been 
autoclaved. Mini-cultures (10 × 10 mL) were incubated (16 h, 37 °C, orbital incubator, 250 r.p.m.,) before inocu-
lating 9 × 1 L to give cultures of OD620 ~0.03. After incubation (37 °C, 240 min, orbital, 250 r.p.m., average OD620 
0.4), three cultures were mixed together to make the 4 h control time point and cells harvested (fixed-angle rotor, 
6k × g, 10 min, 4 °C). Three cultures were treated with RIF (50 mg/L final concentration, added as methanolic 
solution of 50 mg/mL). After 360 min h, the three remaining control cultures were mixed and harvested together 
(making the 6 h control time point which is equivalent to the point at which the cultures treated with RIF are 
arrested), and after 480 min the remaining three cultures treated with RIF were harvested together.
Fluorescence and light microscopy. Cells were photographed after harvesting and before the administra-
tion of lipase inhibitors. Cells were stained with Nile Red as previously described73–75. Briefly, cells were collected 
by centrifugation (fixed-angle rotor, 6 k × g, 10 min, 4 °C), washed once with PBS and resuspended in PBS at 
OD620 ~2.0. Nile Red (2 µg/mL, sample volume 1 mL, dye stock solution in DMSO) was added and the sam-
ple (1 mL) allowed to stand at room temperature (20 min). Cells (60–80 per picture, 180–200 per sample) were 
measured from at least three images for each culture/time point each from four independent cultivations (i.e. 
(~70 × 3) × 3 × 4). The mean and standard deviation were calculated for each and an independent student t-test 
was used to determine statistical significance (p = < 0.01). The null hypothesis was that the lengths of the bacteria 
are the same for each sample. Images were taken using a Leica DMI6000 B microscope equipped with a Leica 
DFC350 FX camera and processed with (the 3D deconvolution function in) Leica Application Suite, Advanced 
fluorescence 1.7.0 software with AF6000 configuration and open source ImageJ software.
Isolation of lipid fraction. Fresh cell pellets were resuspended immediately (PBS, 5 mL) and treated with 
PhosSTOP (1 tab/10 mL final concentration, 10 × stock dissolved in PBS), 2-butoxyphenylboronic acid (BPBA, 
2 mg/mL final concentration, ethanolic stock solution 100 mg/mL) and a stored mixture of mutanolysin (50 µg), 
lysozyme (10 mg), RNAase (200 µg) (volume of aliquots 1 mL, glycerol/PBS 1:1, stored at 193 K). The total volume 
of the resulting solutions was 10 mL per sample and they were agitated gently in air tight falcon tubes (50 mL, 
gel staining table, 16–20 h) before being frozen (193 K) and freeze-dried. The freeze-dried material was stored at 
253 K until isolation of the lipid fraction.
The free-flowing powdered cellular matter was mixed with dichloromethane/methanol (20 mL, 3:1, 0.5 mg/
mL triethylammonium chloride, TEAC) and sonicated (sonication bath, 5 min) before being centrifuged (5 min, 
5.25 k × g). The organic solution was decanted and retained. The pellet was mixed with more of the same dichlo-
romethane/methanol mixture (20 mL, 3:1, 0.5 mg/mL TEAC), agitated, centrifuged and the solvent decanted. 
The pellet was then resuspended in a mixture of dichloromethane and water (20 mL, 1:1, separating funnel) and 
diluted with sufficient methanol to make a stable uniphasic solution (~40 mL), and agitated briefly. The mixture 
was then made biphasic by addition of dichloromethane (20 mL). The dichloromethane solution was removed 
and the aqueous solution washed (dichloromethane, 20 mL). TEAC was added to the remaining aqueous solution 
(final concentration of 2 mM, 2 M stock) and the aqueous solution washed with dichloromethane (2 × 20 mL). 
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The combined organic solutions (~130 mL) were filtered through filter paper and concentrated in vacuo before 
storage under nitrogen at 253 K.
Isolation of residual lipidic material. The aqueous phase and precipitate produced during the lipid iso-
lation (above) were freeze-dried together and then treated with acid (H2SO4, 5%, 20 mL, gentle agitation, 24 h, 
r.t.p.). The reaction mixture was quenched (NaHCO3) and freeze-dried. The free-flowing powder was washed 
twice with chloroform. The organic phases were combined and concentrated in vacuo. The remaining material 
(~8 mg/120 mg LF isolated) was dissolved in deuterated chloroform (650 µL) before commencing 1H NMR. The 
integrals of each spectrum were calibrated according to the α-CH2 signal (2.3–2.4 ppm) present (Fig. S4).
Solution phase 31P NMR spectroscopy. Lipid films (10-15 mg) from cultures of L. Innocua were dis-
solved in the CUBO solvent system15, 35, 76 (500 µL/sample). Data acquisition was similar to published work15, 35 
but using a Bruker 400 MHz Avance III HD spectrometer equipped with a 5 mm BBO S1 (smart) probe operating 
at 298 K for all data except that shown in Fig. S5. 31P spectra were acquired at 161.98 MHz using inverse gated 
proton decoupling, with 2048 scans per sample and a spectral width of 19.99 ppm. An overall recovery delay of 
6.5 s was used which gave full relaxation. Data were processed using line broadening of 1.00 Hz prior to zero fill-
ing to 19428 points, Fourier transform and automatic baseline correction. The data for Fig. S5 were acquired on a 
Bruker Avance III 800 MHz spectrometer, equipped with a QCI cryoprobe probe. Acquisition used inverse gated 
proton decoupling. Spectra were averaged over 1312 transients with 3882 complex points with a spectral width of 
14.98 ppm. An overall recovery delay of 8.4 s was used. Data were processed using an exponential line broadening 
window function of 1.5 Hz prior to zero filling to 32768 points, Fourier transform and automatic baseline correc-
tion. All spectra were processed and analysed using (the dcon function in) TopSpin 3.2.
Preparation of fatty acid isolates. Representative samples used for head group profiling were dried in 
vacuo (high-vac pump) before being diluted (H2SO4 97% in methanol, 1:20 v/v final concentration, 5 mL) and 
heated under intermittent agitation (4–6 h, 50 °C). The reaction mixture was quenched (NaHCO3, 1 g) before 
being diluted (H2O, 30 mL; diethyl ether, 20 mL). The mixture was shaken vigorously in a separating funnel 
before the organic fraction was collected. The aqueous solution was washed (diethyl ether, 20 mL). The organic 
solutions were combined and dried in vacuo. The resulting oil (5–10 mg) was dissolved (CDCl3, 500–600 µL) 
and subjected to 1H NMR spectroscopy. δH (500 MHz, 16 scans, CDCl3, calibrated to 7.24 ppm) 3.6 (singlet, 
RCH2CH2COOCH3), 2.3 (triplet, J = 7.6 Hz, RCH2CH2COOCH3), 1.6-1.5 (m, RCH2CH2COOCH3), 1.4-1.0 (m, 
methylenes), 0.9-0.8 (m, methyl groups) ppm.
Mass spectrometry. Samples were prepared and measurements taken according to published methods15, 35. 
Accurate mass LC-MS and MS/MS was performed on an OrbiTrap Dionex 3000, (Waltham, MA, USA). Dry lipid 
mixtures were dissolved in dichloromethane/isopropanol 1:1 and an inject volume of 10 µL was used. Analytes 
were separated chromatographically on a UPLC C18 column (1.7 µm particle size, Waters) at 40 °C at a rate of 
0.4 mL/min. Mobile phase A consisted of 0.1% formic acid in water at pH 6.0, and mobile phase B was 56% ace-
tonitrile, 40% isopropanol and 5% water with 0.1% formic acid. Ions were monitored in positive mode (m/z range 
300-2000, resolution 140,000). Selected peaks were fragmented (normalised collision energy set to 36) and MS2 
collected with a resolution of 17,500.
Analyses consisted of searches for lipid isoforms in MS1 spectra, followed by fragmentation (MS2) for appro-
priate m/z values. Lipid isoform searches were restricted by head group (PG, PE, PA, PS and CL), FAR (chain 
length from 10 to 20 C, up to three double bonds) and adduct (H+, Na+, K+, NH4+). The search was augmented to 
include lysyl and lyso- isoforms. Matches were compared (see Fig. S6 for example). The software-generated scores 
were checked manually. Analyses were performed using Thermo Xcalibur 3.0.63 and recently-developed software 
by Kochen et al.77. Original code for non-standard head groups was written by us in Matlab R2015b.
Broad line 31P NMR sample preparation. Lipid mixtures were made in solution (dichloromethane, 
10–15 mg/mL) and dried to a lipid film in vacuo. Dried lipid films were dispersed in aqueous buffer (NaCl 
100 mM, tris 50 mM, CaCl2 2.5 mM, MgCl2 2.5 mM, pH 7.4; 30:1 v/w) with sonication and agitation. Deuterium 
oxide (10% v/v against buffer) was added and the mixture agitated and then freeze-thawed 8–10 times. Samples 
were then stored at 193 K, transported at ~295 K and were stored at 253 K before running.
Broad line 31P NMR spectroscopy. A Bruker Avance III HD 400 MHz DRX spectrometer equipped with 
a Bruker BBO S1 (smart) probe was used for proton-decoupled broad line 31P NMR experiments. Experiments 
were performed at 161.98 MHz with an inverse-gated pulse sequence with proton decoupling during acquisition, 
spectral width of 200.44 ppm, acquisition time of 0.299 s, pre-scan delay (DE) time of 20 µs, receiver gain of 203 
with 19428 data points and 2048 scans per spectrum. The duration of each scan, acquisition time and relaxation 
delay, was 2.332 s. Spectra were processed using TopSpin 3.2 and 3.5 with line broadening of 50 Hz, phase correc-
tion and automatic baseline correction (abs).
Broad line 31P NMR temperature scans. Samples were brought to and held at the desired temperature 
for 15 min before acquisition. Temperature scans consisted of acquisitions at the following temperatures: 298, 273, 
293, 298, 310, 318, 273, 310 K. The latter two temperature points were used to assess the reliability of the equili-
bration time used (15 min). Acquisitions at 338 K were carried out separately with equilibration and acquisition 
at 310 K immediately beforehand. Stackplots of spectra were prepared manually from individual traces processed 
as above.
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Figure S1. Experimental steps following preparation of the exponentially growing cultures. After harvesting, each culture 
was pelleted. Microscopy was performed to determine the morphology of the cells under study and for measurement of cell 
length and calculation of cell length distribution. Pelleting was followed by digestion of the cell wall in the presence of lipase 
inhibitors. The resulting material was then freeze-dried and the lipid fraction isolated. Finally, the lipid fraction was 
dispersed in CUBO solvent15,35,49,76-78 for profiling using 31P NMR and in isopropanol/dichloromethane (1:1 v/v) for profiling 
using MS. 
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Figure S2. 1H NMR traces of fatty acid methyl esters isolated from lipid fractions of E. coli (trace A) and L. innocua (trace B), 
with example structures shown inset. The resonances corresponding to particular proton nuclei are marked (a-k), with a key 
on inset structures. The integrations of the appropriate signals indicate that around 40% of the FARs in the E. coli sample 
possess a cyclopropyl ring (b compared to g,h,i) and that the average number of methyl branches per FAR in Listeria is at 
least one (b compared to k). 
 
 
   
 
Figure S3. Two representative 1H NMR spectra of chloroform-soluble material from the dried and acid-treated remaining 
(aqueous/precipitate) fraction of the lipid isolation. The effectiveness of the isolation procedure developed in this study was 
tested by an attempt to isolate remaining fatty acid residues. The aqueous solution and precipitate were dried together and 
then treated with strong acid in order to hydrolyse any ester bond present, before being dried and washed with chloroform. 
The dried oil was subject to 1H NMR spectroscopy. The integrations of the signals are calibrated by the α-CH2 signal (signal b, 
2.3-2.4 ppm). This indicates that the integration of other signals (e.g. methyl signals, k, 0.6-0.8 ppm) are much higher than 
can be ascribed to FAMEs alone (~25H. The integration of one methyl group is 3H, indicating that there was an average of 8 
protons in this chemical environment per FAR present). The complexity of the methyl signal and others also suggests the 
presence of other (lipophilic) species. The fraction of FAs present (25H/8H) was therefore judged as ~30% w/w (mean n = 4 
measurements).  
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Figure S4. 31P NMR (323.96 MHz) spectra for indicating lysyl-phosphatidylglycerol in lipid mixtures. Stacked traces of lecithin 
from Helianthus mixed with lysyl-DOPG (A) and as supplied (B), indicating that the resonances for the two structural isomers 
of lysyl-DOPG are at ~0.7 and 0.9 ppm, representing the isomers with the lysyl groups on the primary and secondary 
hydroxyls of the head group’s glyceryl moiety, respectively.  
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  Cell cycle profile Phospholipid profiling 
B period 
 (4h) 








Cell length  
(µm, p = 
<0.001) 
1.24 ± 0.29 1.22 ± 0.37 1.92 ± 0.44 - - 
OD620 at 
harvest 
0.50 ± 0.14 1.57 ± 0.18 0.79 ± 0.05 - - 
PG 32.7 % ± 8.4 % 50.9 % ± 10.6 % 43.3 % ± 14.4 % 1.23-1.28 
637.4079 (C11:0/15:0); 665.4399 (C14:0/14:0); 
679.4556 (C14:0/15:0); 693.4718 (C15:0/15:0); 
705.4712 (C15:0/16:1); 707.4874 (C15:0/16:0); 
721.5030 (C15:0/17:0; C16:0/16:0); 733.5025 
(C15:0/18:1); 735.5187 (C16:0/17:0); 749.5338 
(C17:0/17:0) 
CL 27.6 % ± 4.8 % 20.1 % ± 5.1 % 15.6 % ± 5.8 % 0.77 
1098.7113 (C15:0/15:0/17:0/0:0); 1127.7504 
(C17:0/15:0/17:0/0:0; C19:0/15:0/15:0/0:0). 















1362.9562 (C17:0/15:0/18:1/15:0); 1364.9719 
(C16:0/16:0/17:0/16:0); 1378.9875 
(C15:0/17:0/17:0/17:0); 




690.5084 (15:0/17:0); 704.5241 (C16:0/17:0); 
718.5398 (C17:0/17:0; C15:/19:0) 
lysyl-PG† 2.8 % ± 3.1 % 5.8 % ± 3.4 % 4.3 % ± 4.1 % 0.69 
807.5506 (C14:0/15:0); 821.5668 (15:0/15:0); 
835.5824 (C15:0/16:0); 849.5980 (C15:0/17:0; 
C16:0/16:0); 877.6288 (C17:0/17:0) 
lyso-PA 0.6 % ± 0.7 % 0.3 % ± 0.4 % 1.8 % ± 1.0 % 6.0-6.3b 423.2510 (C17:0); 451.2823 (C19:0) 
PA 2.5 % ± 3.4 % 3.5 % ± 2.0 % 5.0 % ± 3.6 % 4.8-5.3b 
647.4663 (C15:0/17:0); 661.4819 (C16:0/17:0); 
675.4976 (C15:0/19:0; C17:0/17:0); 703.5283 
(C17:0/19:0) 
lysyl-CL‡ 4.4 % ± 2.9 % 1.6 % ± 2.3 % 13.1 % ± 12.7 % 0.63‡ 
1395.8457 (C58:0); 1409.8723 (C59:0); 1423.8990 
(C60:0); 1437.9256 (C61:0) 
PS 0.7 % ± 1.4 % 0.8 % ± 0.9 % 0.4 % 
± 0.3 % 
0.52 
706.0507 (C15:0/15:0); 721.4888 (C15:0/16:0; 
C14:0/17:0); 734.4937 (C15:0/17:0); 748.5093 
(C16:0/17:0); 762.5250 (C17:0/17:0); 790.5604 
(C17:0/19:0) 
lyso-PG n/d  3.5 % ± 3.2 % 2.0 % 
± 2.0 % 
 
456.2488 (C14:0); 470.2644 (C15:0); 484.2801 
(C16:0); 498.2957 (C17:0).  
Others <5 %  <5 %  <5 %  Var. - 
Table S1. Cell length and lipid head group profile of L. innocua NCTC 11288. Cell length distributions determined through 
measurement of cells on micrographs (Fig. 1, p = <0.01, independent samples students’ t-test), lipid profile determined using 
31P NMR and MS from n = 5 isolates. *HRMS/MS performed in positive ion mode; masses given are the m/z less the adducts. 
Assignments in 31P spectra were made using literature references35,76-78 and †stacked 1D data from this study (Fig. S4). The 
FAs identified by MS are consistent with previous studies of Listeria spp.51,79,80. ‡Tentative assignment. aPE exhibits several 
shifts in vitro due to interactions with the solvent and as a function of pH and concentration. bThe shift of phosphate mono-
ester-containing lipids is pH dependent. 
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Figure S5. Representative fragmentation spectrum of a lipid (isoform PG(15:0, 17:0)) from Listeria innocua. Only spectra in 
which fragmentation that described the lipid unambiguously were used to support identification. The data was acquired on 
an OrbiTrap Dionex 3000, (Waltham, MA, USA). Briefly, dry lipid mixtures were solubilized using a 
dichloromethane/isopropanol 1:1 mixture. The samples from this solution was injected (10 µL) and lipids separated by 
chromatography using a UPLC C18 column (1.7 µm particle size, Waters, 40°C, and flow rate of 0.4 mL/min). Ions were 
detected in positive mode, and MS data were analysed using software from Kochen et al.75, and Matlab code developed by 
authors. Only spectra in which fragmentation that described the lipid unambiguously were used to support identification.  
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Figure S6. Representative 1H NMR spectra of fatty acid methyl ester preparations of lipid fractions isolated used for head 
group profiling. Resonances as described in the Experimental, with example labelled as inset structure. *resonance 
pertaining to grease (1.45 ppm), that overlaps with that of the β-CH2 signal (c, 1.6 ppm). There was no evidence for the 




Figure S7. Broad line 31P NMR temperature scans of hydrated single-lipid systems. A, TOCL; B, DOPG; C, DOPE.   
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Figure S8. Broad line 31P NMR (161.98 MHz) temperature scans of hydrated mixtures of DOPG and TOCL (A-C) and lysyl-
DOPG and TOCL (D). A, 1:1 molar ratio of DOPG and TOCL; B, 3:1 molar ratio; C, 10:1 molar ratio; D, 10:1 molar ratio of 
TOCL and lysyl-DOPG.  
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Figure S9. Broad line 31P NMR (161.98 MHz) temperature scans of hydrated mixtures of DOPG and DOPE (A-E) and lysyl-
DOPG and DOPE (F). A, 82:18 molar ratio of DOPG and DOPE; B, 36:64 molar ratio; C, 1:1 molar ratio; D, 1:13 molar ratio; E, 
1:22 molar ratio; F, 1:22 molar ration of lysyl-DOPG and PE.  
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Figure S10. Broad line 31P NMR (161.98 MHz) temperature scans of hydrated mixtures of TOCL and DOPE. A, 8:1 molar ratio 
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